<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65145</article-id><article-id pub-id-type="doi">10.7554/eLife.65145</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-216756"><name><surname>Staquicini</surname><given-names>Fernanda I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1137-6575</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">‡</xref></contrib><contrib contrib-type="author" id="author-216757"><name><surname>Hajitou</surname><given-names>Amin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216758"><name><surname>Driessen</surname><given-names>Wouter HP</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa2">§</xref></contrib><contrib contrib-type="author" id="author-216759"><name><surname>Proneth</surname><given-names>Bettina</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216760"><name><surname>Cardó-Vila</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216761"><name><surname>Staquicini</surname><given-names>Daniela I</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216762"><name><surname>Markosian</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216763"><name><surname>Hoh</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa3">#</xref></contrib><contrib contrib-type="author" id="author-5351"><name><surname>Cortez</surname><given-names>Mauro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6536-4647</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund15"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216764"><name><surname>Hooda-Nehra</surname><given-names>Anupama</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216765"><name><surname>Jaloudi</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-31917"><name><surname>Silva</surname><given-names>Israel T</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216766"><name><surname>Buttura</surname><given-names>Jaqueline</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216767"><name><surname>Nunes</surname><given-names>Diana</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216768"><name><surname>Dias-Neto</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216769"><name><surname>Eckhardt</surname><given-names>Bedrich</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216770"><name><surname>Ruiz-Ramírez</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216771"><name><surname>Dogra</surname><given-names>Prashant</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216772"><name><surname>Wang</surname><given-names>Zhihui</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216773"><name><surname>Cristini</surname><given-names>Vittorio</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216774"><name><surname>Trepel</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216775"><name><surname>Anderson</surname><given-names>Robin</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216776"><name><surname>Sidman</surname><given-names>Richard L</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216777"><name><surname>Gelovani</surname><given-names>Juri G</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf2"/><xref ref-type="fn" rid="pa4">¶</xref></contrib><contrib contrib-type="author" id="author-216778"><name><surname>Cristofanilli</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="aff21">21</xref><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216779"><name><surname>Hortobagy</surname><given-names>Gabriel</given-names></name><xref ref-type="aff" rid="aff22">22</xref><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216780"><name><surname>Bhujwalla</surname><given-names>Zaver M</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con27"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216781"><name><surname>Burley</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff23">23</xref><xref ref-type="aff" rid="aff24">24</xref><xref ref-type="aff" rid="aff25">25</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con28"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-216139"><name><surname>Arap</surname><given-names>Wadih</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8686-4584</contrib-id><email>wa116@newark.rutgers.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con29"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-216782"><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><email>rp946@rutgers.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con30"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution>Rutgers Cancer Institute of New Jersey</institution><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School</institution><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Phage Therapy Group, Department of Brain Sciences, Imperial College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution>The University of Texas M.D. Anderson Cancer Center</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Institute of Metabolism and Cell Death, Helmholtz Zentrum Muenchen</institution><addr-line><named-content content-type="city">Neuherberg</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution>Department of Cellular and Molecular Medicine, The University of Arizona Cancer Center, University of Arizona</institution><addr-line><named-content content-type="city">Tucson</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Department of Otolaryngology-Head and Neck Surgery, The University of Arizona Cancer Center, University of Arizona</institution><addr-line><named-content content-type="city">Tucson</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>Division of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo</institution><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff10"><label>10</label><institution>Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School</institution><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution>Laboratory of Computational Biology, A.C. Camargo Cancer Center</institution><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff12"><label>12</label><institution>Laboratory of Medical Genomics, A.C. Camargo Cancer Center</institution><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff13"><label>13</label><institution>Translational Breast Cancer Program, Olivia Newton-John Cancer Research Institute</institution><addr-line><named-content content-type="city">Melbourne</named-content></addr-line><country>Australia</country></aff><aff id="aff14"><label>14</label><institution>Mathematics in Medicine Program, The Houston Methodist Research Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff15"><label>15</label><institution>Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf</institution><addr-line><named-content content-type="city">Hamburg</named-content></addr-line><country>Germany</country></aff><aff id="aff16"><label>16</label><institution>Department of Oncology and Hematology, University Medical Center Augsburg</institution><addr-line><named-content content-type="city">Augsburg</named-content></addr-line><country>Germany</country></aff><aff id="aff17"><label>17</label><institution>Department of Neurology, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff18"><label>18</label><institution>Department of Biomedical Engineering, College of Engineering, Wayne State University</institution><addr-line><named-content content-type="city">Detroit</named-content></addr-line><country>United States</country></aff><aff id="aff19"><label>19</label><institution>Department of Oncology, School of Medicine, Wayne State University</institution><addr-line><named-content content-type="city">Detroit</named-content></addr-line><country>United States</country></aff><aff id="aff20"><label>20</label><institution>Department of Neurosurgery, School of Medicine, Wayne State University</institution><addr-line><named-content content-type="city">Detroit</named-content></addr-line><country>United States</country></aff><aff id="aff21"><label>21</label><institution>Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff22"><label>22</label><institution>Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff23"><label>23</label><institution>Rutgers Cancer Institute of New Jersey</institution><addr-line><named-content content-type="city">New Brunswick</named-content></addr-line><country>United States</country></aff><aff id="aff24"><label>24</label><institution>Research Collaboratory for Structural Bioinformatics Protein Data Bank, San Diego Supercomputer Center, University of California-San Diego</institution><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff><aff id="aff25"><label>25</label><institution>Research Collaboratory for Structural Bioinformatics Protein Data Bank, Institute for Quantitative Biomedicine, Rutgers, The State University of New Jersey</institution><addr-line><named-content content-type="city">Piscataway</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing Editor</role><aff><institution>James J Peters Veterans Affairs Medical Center</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>‡</label><p>MBrace Therapeutics, TO Daniel Research Incubator and Collaboration Center, Summit, United States</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland</p></fn><fn fn-type="present-address" id="pa3"><label>#</label><p>Department of Pharmacology, School of Medicine, University of Colorado, Aurora, United States</p></fn><fn fn-type="present-address" id="pa4"><label>¶</label><p>Office of the Provost, United Arab Emirates University, Al Ain, United Arab Emirates</p></fn><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>01</day><month>06</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e65145</elocation-id><history><date date-type="received" iso-8601-date="2020-11-24"><day>24</day><month>11</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-04-23"><day>23</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Staquicini et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Staquicini et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-65145-v1.pdf"/><abstract><p>Triple-negative breast cancer (TNBC) is an aggressive tumor with limited treatment options and poor prognosis. We applied the in vivo phage display technology to isolate peptides homing to the immunosuppressive cellular microenvironment of TNBC as a strategy for non-malignant target discovery. We identified a cyclic peptide (CSSTRESAC) that specifically binds to a vitamin D receptor, protein disulfide-isomerase A3 (PDIA3) expressed on the cell surface of tumor-associated macrophages (TAM), and targets breast cancer in syngeneic TNBC, non-TNBC xenograft, and transgenic mouse models. Systemic administration of CSSTRESAC to TNBC-bearing mice shifted the cytokine profile toward an antitumor immune response and delayed tumor growth. Moreover, CSSTRESAC enabled ligand-directed theranostic delivery to tumors and a mathematical model confirmed our experimental findings. Finally, in silico analysis showed PDIA3-expressing TAM in TNBC patients. This work uncovers a functional interplay between a cell surface vitamin D receptor in TAM and antitumor immune response that could be therapeutically exploited.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>vitamin D receptor</kwd><kwd>tumor-associated macrophage</kwd><kwd>triple-negative breast cancer</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>W81XWH-09-1-0224</award-id><principal-award-recipient><name><surname>Staquicini</surname><given-names>Fernanda I</given-names></name><name><surname>Hajitou</surname><given-names>Amin</given-names></name><name><surname>Driessen</surname><given-names>Wouter HP</given-names></name><name><surname>Proneth</surname><given-names>Bettina</given-names></name><name><surname>Cardó-Vila</surname><given-names>Marina</given-names></name><name><surname>Staquicini</surname><given-names>Daniela I</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Gilson Logenbaugh Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Staquicini</surname><given-names>Fernanda</given-names></name><name><surname>Hajitou</surname><given-names>Amin</given-names></name><name><surname>Driessen</surname><given-names>Wouter HP</given-names></name><name><surname>Proneth</surname><given-names>Bettina</given-names></name><name><surname>Cardó-Vila</surname><given-names>Marina</given-names></name><name><surname>Staquicini</surname><given-names>Daniela</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009634</institution-id><institution>Susan G. Komen</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Staquicini</surname><given-names>Fernanda</given-names></name><name><surname>Hajitou</surname><given-names>Amin</given-names></name><name><surname>Driessen</surname><given-names>Wouter HP</given-names></name><name><surname>Proneth</surname><given-names>Bettina</given-names></name><name><surname>Cardó-Vila</surname><given-names>Marina</given-names></name><name><surname>Staquicini</surname><given-names>Daniela</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>DBI-1832184</award-id><principal-award-recipient><name><surname>Markosian</surname><given-names>Christopher</given-names></name><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name><name><surname>Burley</surname><given-names>Stephen</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01GM133198</award-id><principal-award-recipient><name><surname>Staquicini</surname><given-names>Fernanda</given-names></name><name><surname>Hajitou</surname><given-names>Amin</given-names></name><name><surname>Driessen</surname><given-names>Wouter HP</given-names></name><name><surname>Proneth</surname><given-names>Bettina</given-names></name><name><surname>Cardó-Vila</surname><given-names>Marina</given-names></name><name><surname>Staquicini</surname><given-names>Daniela</given-names></name><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name><name><surname>Burley</surname><given-names>Stephen</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000015</institution-id><institution>U.S. Department of Energy</institution></institution-wrap></funding-source><award-id>DE-SC0019749</award-id><principal-award-recipient><name><surname>Burley</surname><given-names>Stephen</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>2012/24105-3</award-id><principal-award-recipient><name><surname>Cortez</surname><given-names>Mauro</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>DMS-1930583</award-id><principal-award-recipient><name><surname>Markosian</surname><given-names>Christopher</given-names></name><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1U01CA196403</award-id><principal-award-recipient><name><surname>Staquicini</surname><given-names>Fernanda</given-names></name><name><surname>Hajitou</surname><given-names>Amin</given-names></name><name><surname>Driessen</surname><given-names>Wouter HP</given-names></name><name><surname>Proneth</surname><given-names>Bettina</given-names></name><name><surname>Cardó-Vila</surname><given-names>Marina</given-names></name><name><surname>Staquicini</surname><given-names>Daniela</given-names></name><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name><name><surname>Burley</surname><given-names>Stephen</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1U01CA213759</award-id><principal-award-recipient><name><surname>Staquicini</surname><given-names>Fernanda</given-names></name><name><surname>Hajitou</surname><given-names>Amin</given-names></name><name><surname>Driessen</surname><given-names>Wouter HP</given-names></name><name><surname>Proneth</surname><given-names>Bettina</given-names></name><name><surname>Cardó-Vila</surname><given-names>Marina</given-names></name><name><surname>Staquicini</surname><given-names>Daniela</given-names></name><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name><name><surname>Burley</surname><given-names>Stephen</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1R01CA226537</award-id><principal-award-recipient><name><surname>Staquicini</surname><given-names>Fernanda</given-names></name><name><surname>Hajitou</surname><given-names>Amin</given-names></name><name><surname>Driessen</surname><given-names>Wouter HP</given-names></name><name><surname>Proneth</surname><given-names>Bettina</given-names></name><name><surname>Cardó-Vila</surname><given-names>Marina</given-names></name><name><surname>Staquicini</surname><given-names>Daniela</given-names></name><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name><name><surname>Burley</surname><given-names>Stephen</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1R01CA222007</award-id><principal-award-recipient><name><surname>Staquicini</surname><given-names>Fernanda</given-names></name><name><surname>Hajitou</surname><given-names>Amin</given-names></name><name><surname>Driessen</surname><given-names>Wouter HP</given-names></name><name><surname>Proneth</surname><given-names>Bettina</given-names></name><name><surname>Cardó-Vila</surname><given-names>Marina</given-names></name><name><surname>Staquicini</surname><given-names>Daniela</given-names></name><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name><name><surname>Burley</surname><given-names>Stephen</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U54CA210181</award-id><principal-award-recipient><name><surname>Staquicini</surname><given-names>Fernanda</given-names></name><name><surname>Hajitou</surname><given-names>Amin</given-names></name><name><surname>Driessen</surname><given-names>Wouter HP</given-names></name><name><surname>Proneth</surname><given-names>Bettina</given-names></name><name><surname>Cardó-Vila</surname><given-names>Marina</given-names></name><name><surname>Staquicini</surname><given-names>Daniela</given-names></name><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name><name><surname>Burley</surname><given-names>Stephen</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id><institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution></institution-wrap></funding-source><award-id>2020/13562-0</award-id><principal-award-recipient><name><surname>Cortez</surname><given-names>Mauro</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A peptide motif targeting tumor-infiltrating macrophage in triple-negative breast cancer delays tumor growth and favors an antitumor immune response.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Breast cancer is the second most common cancer type worldwide, and triple-negative breast cancer (TNBC) comprises up to ~10–20% of all cases. These heterogeneous tumors are clinically aggressive, usually with larger sizes at initial presentation, of high pathological grade, and likely to have lymph node involvement and early recurrence in visceral sites (<xref ref-type="bibr" rid="bib13">Dietze et al., 2015</xref>; <xref ref-type="bibr" rid="bib31">Newman and Kaljee, 2017</xref>; <xref ref-type="bibr" rid="bib39">Schettini et al., 2016</xref>). TNBC is treated with multimodality therapy including neoadjuvant chemotherapy, surgery and adjuvant radiotherapy, with selected patients receiving additional adjuvant systemic therapy. Despite optimal management, many patients have distant metastases and poor disease outcomes (<xref ref-type="bibr" rid="bib3">Biswas et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">Coughlin, 2019</xref>; <xref ref-type="bibr" rid="bib12">Dent et al., 2007</xref>; <xref ref-type="bibr" rid="bib36">Perou et al., 2000</xref>). Combination chemotherapy has long been the standard therapeutic option but checkpoint inhibitors and poly ADP-ribose polymerase (PARP) inhibitors have recently been approved in certain settings (<xref ref-type="bibr" rid="bib17">Garrido-Castro et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Khan et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Lyons and Traina, 2019</xref>; <xref ref-type="bibr" rid="bib29">Marra et al., 2019</xref>).</p><p>Immunomodulators are among the best available investigational drugs for this tumor subtype, based on the premise that manipulation of the local and/or distant immune responses may ultimately represent a viable treatment approach (<xref ref-type="bibr" rid="bib29">Marra et al., 2019</xref>). A biological hallmark of TNBC is an immunosuppressive tumor microenvironment that fosters tumor growth and metastatic spread through the suppression of tumor-infiltrating lymphocytes and secretion of immunoinhibitory cytokines, mainly by tumor-associated macrophages (TAM) (<xref ref-type="bibr" rid="bib11">DeNardo and Ruffell, 2019</xref>; <xref ref-type="bibr" rid="bib25">Lim et al., 2018</xref>; <xref ref-type="bibr" rid="bib47">Wagner et al., 2019</xref>). TAM are classically divided into two major populations, M1 and M2, representing the extremes of a broad activation state spectrum; the M1 population is associated with antitumor activity while the M2 population with tumor progression (<xref ref-type="bibr" rid="bib11">DeNardo and Ruffell, 2019</xref>; <xref ref-type="bibr" rid="bib25">Lim et al., 2018</xref>; <xref ref-type="bibr" rid="bib47">Wagner et al., 2019</xref>; <xref ref-type="bibr" rid="bib4">Biswas and Mantovani, 2010</xref>; <xref ref-type="bibr" rid="bib44">Tan et al., 2019</xref>). Such biological behavior in breast cancer has made them potentially attractive targets for therapeutic intervention. In fact, TAM-targeting drugs are currently in clinical trials but have not yet been approved for clinical practice.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Combinatorial phage display screening in vivo reveals tumor microenvironment-binding peptides in a mouse model of TNBC</title><p>We used a phage display-based approach to identify homing peptides that target TAM in TNBC. The EF43.<italic>fgf4</italic> syngeneic mouse mammary gland tumor (<xref ref-type="bibr" rid="bib1">Adams et al., 1987</xref>; <xref ref-type="bibr" rid="bib21">Hajitou et al., 1998</xref>) is highly infiltrated by TAM and also serves as an immunocompetent TNBC model since EF43.<italic>fgf4</italic> cells do not express the estrogen receptor, progesterone receptor, or <italic>Erbb2/</italic>Neu (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). A random phage peptide library was first administered intravenously (iv) in immunocompetent female BALB/c mice with established EF43.<italic>fgf4</italic>-derived mammary fat pad tumors. Phage particles were recovered from tumors after 24 hr, re-amplified, and subjected to two additional rounds of in vivo selection. After the third round, the pool of tumor-homing phage showed an ~300 fold enrichment relative to normal tissues (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Bioinformatic analysis of peptides targeting the whole tumor revealed four sequences above an experimental threshold (set at 1%): CSSTRESAC, CRYSAARSC, CRGFVVGRC, and CQRALMIAC (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Notably, the dominant peptide CSSTRESAC was more strongly enriched (16-fold) than each of the other three peptides (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The four selected peptides were next individually evaluated based on absence of binding to EF43.<italic>fgf4</italic> cells in vitro (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). With a standard cell binding assay (<xref ref-type="bibr" rid="bib18">Giordano et al., 2001</xref>), we found that the peptides CRGFVVGRC, CQRALMIAC, and CRYSAARSC bound to EF43.<italic>fgf4</italic> cells, whereas the peptide CSSTRESAC did not (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), indicating that CSSTRESAC might indeed recognize non-malignant stromal cells within the tumor microenvironment. The peptides CRGFVVGRC, CQRALMIAC, and CRYSAARSC were not studied further.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Combinatorial targeting of the tumor cellular microenvironment in a mouse model of TNBC.</title><p>(<bold>A</bold>) A random phage display peptide library displaying CX7C inserts (C, cysteine; X any seven residues) was used in vivo to select peptides homing to the microenvironment of EF43.fgf4-derived mammary tumors. Three sequential rounds of selection resulted in a pool of targeted phage particles with a 300-fold enrichment in the tumor, compared to a control organ (muscle). (<bold>B</bold>) Binding of individual phage clones to EF43.fgf4 cells was quantified by the counting of transducing units (TU) after host bacterial infection. (<bold>C</bold>) Binding of CSSTRESAC-phage to EF43.fgf4 tumor cells and non-malignant stromal cell subpopulations isolated from mCherry-expressing EF43.fgf4-derived mammary tumors. (<bold>D</bold>) Relative binding of the CSSTRESAC-phage or insertless control phage to fractions eluted from a CSSTRESAC-conjugated affinity purification column. BSA was used as negative control protein. (<bold>E</bold>) Immunoblottings developed with either anti-PDIA3 (top panel) or anti-DBP (lower panel) antibodies show the presence of both affinity-purified proteins in the experimental fraction F#5 but not in the negative control fraction F#9. Human recombinant PDIA3-GST and DBP-GST were used as control for antibody specificity. (<bold>F</bold>) Phage-binding assay confirms preferential binding of targeted CSSTRESAC-phage to the recombinant human DBP. GST and BSA were used as negative controls. (<bold>G</bold>) Predicted structure of CSSTRESAC peptide, including a 2.0 Å-disulfide bridge between Cys1 and Cys9, as visualized with UCSF Chimera. (<bold>H</bold>) Predicted binding conformation and orientation of CSSTRESAC relative to the crystal structure of DBP in a hydrophobicity surface view (PDB ID: 1KW2_A). Orange and blue represent hydrophobic and hydrophilic patches, respectively. (<bold>I</bold>) Key predicted non-hydrophobic interactions between CSSTRESAC and DBP (PDB ID: 1KW2_A), including a 2.9 Å-salt bridge between Cys1 and Glu24, a 2.9 Å-salt bridge between Glu6 and Lys51, and a 2.9 Å-hydrogen bond between Ala8 and Glu24. CSSTRESAC also blocks access to Tyr48 and Ser92 (Tyr32 and Ser76 in PDB ID: 1J78), which correspond to predicted key residues of DBP interaction with 1,25-(OH)<sub>2</sub>D<sub>3</sub>. (<bold>J</bold>) Crystal structure of 25-(OH)D<sub>3</sub> bound to DBP in a hydrophobicity surface view (PDB ID: 1J78). Orange and blue represent hydrophobic and hydrophilic patches, respectively. (<bold>K</bold>) Binding of CSSTRESAC-phage to DBP is inhibited by the active form of vitamin D [1,25-(OH)<sub>2</sub>D<sub>3</sub>], but not by its corresponding vitamin D3 precursor (* represents Student’s t-test, p&lt;0.05).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>EF43.fgf4-derived tumor is a model of triple negative mammary cancer.</title><p>(<bold>A</bold>) Immunoblotting analysis of estrogen receptor (ER), progesterone receptor (PR) and HER-2/Neu in several breast cancer cell lines confirming that EF43.fgf4 cancer cells are a triple-negative mammary cancer model. (<bold>B</bold>) Quantitative analysis of peptide sequences obtained from the third round of in vivo phage display library screening in EF43.fgf4-tumor bearing mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Macrophages are a major component of EF43.fgf4 mammary tumors.</title><p>(<bold>A – C</bold>) Flow cytometry analysis of total cells isolated from mCherry-expressing EF43.fgf4 mammary tumors. A major component of infiltrating non-malignant cells expresses the macrophage markers CD11b and F4/80 (<bold>A</bold>). (<bold>B</bold>) B-lymphocytes expressing the common leukocyte antigen CD45.2, and the B-cell lineage marker CD45R were also found, although in small quantities. (<bold>C</bold>) T-lymphocytes, as identified by the T-cell markers CD8 and CD4 were also tested but not detected.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>The CSSTRESAC peptide targets breast cancer in various mouse models.</title><p>(<bold>A</bold>) The MMTV-PyMT mouse model of breast cancer was used to confirm targeting of the CSSTRESAC-phage in vivo. Skeletal muscle was used as a negative control tissue. (<bold>B</bold>) CSSTRESAC-targeted liposomes loaded with gadolinium (n = 13) or control liposomes (n = 8) were administered iv to MDA-MB-231-bearing mice and MRI measurements (T1-weighted) were acquired at several time points post-administration. An increased contrast enhancement in breast tumor xenografts receiving CSSTRESAC-targeted liposomes was clearly detected after 3 hr of systemic circulation and persisted through 24 and 48 hr (<bold>B-C</bold>) compared to control liposomes. (<bold>C</bold>) Quantitative T1 maps showing significantly shorter T1 relaxation times (t-test, p&lt;0.025) for the CSSTRESAC-targeted liposomes at 3, 6, and 72 hr post-administration. (<bold>D</bold>) Biodistribution of liposomes at 48 hr was examined by measuring the T1 values of excised tumors, control organs, and blood. This ex vivo analysis, along with MRI measurements, confirmed that CSSTRESAC-targeted liposomes preferentially accumulated in MDA-MB-231 breast tumor xenografts, compared to control liposomes. No differences were detected in several control tissues and organs. (<bold>E, F</bold>) Localization of CSSTRESAC-targeted liposomes in MDA-MB-231 breast tumor xenografts was confirmed by double-fluorescent liposomes in which the ligand CSSTRESAC was labeled with FITC (green), and lipids composing the liposomes were labeled with rhodamine (red). Fluorescence was quantified ex vivo in a Xenogen imaging system with tumor tissue collected at 24, 48, and 72 hr post-iv administration of targeted and control double-fluorescent liposomes. Fluorescence quantification revealed a fivefold higher accumulation of CSSTRESAC-targeted liposomes in tumors as fast as 24 hr post-administration relative to control liposomes. The differential accumulation of CSSTRESAC-targeted liposomes in MDA-MB-231 breast tumor xenografts became less pronounced, yet still statistically significant (t-test, p&lt;0.01), at 48 and 72 hr.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>CSSTRESAC-targeted liposomes do not cause toxicity in mice.</title><p>(<bold>A</bold>) Fluorescence imaging experiments were performed on several control organs and normalized to a defined control tissue (skeletal muscle). Liposome uptake was low in all organs except the liver, a well-known biological phenomenon due to the relatively large size and cationic charge of liposomes (targeted or control), and their non-specific uptake by the reticuloendothelial system. (<bold>B</bold>) None of the liposome preparations caused liver toxicity as confirmed by levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) measured in serum of treated mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig1-figsupp4-v1.tif"/></fig></fig-group><p>To identify the non-malignant cellular component(s) targeted by CSSTRESAC-phage, we tested binding to subcellular populations freshly isolated from engrafted tumors. mCherry-expressing EF43.<italic>fgf4</italic> cells were FACS-sorted from whole tumors. The remaining cells were subsequently FACS-sorted based on expression of CD45 (Leukocyte Common Antigen, LCA) and F4/80, respectively. Similar to human breast cancers known to be highly infiltrated by macrophages (<xref ref-type="bibr" rid="bib3">Biswas et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Dent et al., 2007</xref>; <xref ref-type="bibr" rid="bib36">Perou et al., 2000</xref>; <xref ref-type="bibr" rid="bib17">Garrido-Castro et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Khan et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Marra et al., 2019</xref>; <xref ref-type="bibr" rid="bib11">DeNardo and Ruffell, 2019</xref>; <xref ref-type="bibr" rid="bib25">Lim et al., 2018</xref>; <xref ref-type="bibr" rid="bib47">Wagner et al., 2019</xref>; <xref ref-type="bibr" rid="bib4">Biswas and Mantovani, 2010</xref>; <xref ref-type="bibr" rid="bib44">Tan et al., 2019</xref>; <xref ref-type="bibr" rid="bib1">Adams et al., 1987</xref>; <xref ref-type="bibr" rid="bib21">Hajitou et al., 1998</xref>; <xref ref-type="bibr" rid="bib18">Giordano et al., 2001</xref>), the macrophage population (CD11b<sup>+</sup>F4/80<sup>+</sup>) constituted a large portion of the non-malignant cellular component of EF43.<italic>fgf4</italic>-derived mammary tumors, followed by a lesser population of B lymphocytes (CD45R<sup>+</sup>). T-lymphocytes (CD8<sup>+</sup> or CD4<sup>+</sup>) were not detected (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Binding assays to each of these cell subpopulations showed that CSSTRESAC-phage particles bound specifically to CD11b<sup>+</sup>F4/80<sup>+</sup> macrophage; binding to tumor-isolated EF43.<italic>fgf4</italic> cells and CD45R<sup>+</sup> cells were at background levels (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Based on these results, we concluded that CSSTRESAC-phage particles target a TAM cell surface receptor.</p><p>Although we showed that the CSSTRESAC-phage targeted TAM in a syngeneic TNBC model, we considered that it might be able to target the tumor microenvironment in other experimental models of non-TNBC breast cancer also known to be infiltrated by TAM. First, we tested CSSTRESAC-phage homing in the mouse mammary tumor virus-polyoma middle T-antigen (MMTV-PyMT) transgenic model of breast cancer (<xref ref-type="bibr" rid="bib20">Guy et al., 1992</xref>; <xref ref-type="bibr" rid="bib27">Maglione et al., 2001</xref>). Binding of the CSSTRESAC-phage to MMTV-PyMT tumors was higher compared to a control organ (~3-fold) or to a negative control phage (~2.5-fold) (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>). To determine whether the CSSTRESAC-phage may also target human tumors, we next used MDA-MB-231-bearing mice, a standard non-TNBC breast cancer xenograft model. We tested whether liposomes decorated with either CSSTRESAC or control peptide could target these tumors by using Magnetic Resonance Imaging (MRI) and fluorescence, and found that CSSTRESAC targets human breast cancers in vivo independently of the phage context. (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B–F</xref>). Together, these experiments demonstrate that CSSTRESAC targets a range of different breast tumors (in xenograft, genetic, and syngeneic mouse models) independently of their ligand display context, tumor cell species, or host immunocompetency status. These results also further indicate that the CSSTRESAC peptide may be of value in different types of non-TNBC, and perhaps also other solid tumors containing TAM. Liposome uptake was low in all organs except the liver, a well-known biological phenomenon due to the relatively large size and cationic charge of liposomes (both, targeted or control). None of the liposome preparations caused liver toxicity as confirmed by levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) measured in serum of treated mice (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>).</p><p>Next, we used peptide affinity chromatography (<xref ref-type="bibr" rid="bib42">Staquicini et al., 2009</xref>) to identify the cell surface receptor(s) in TAM targeted by the CSSTRESAC peptide. Interacting proteins were eluted through an excessive amount of soluble CSSTRESAC peptide and subsequently control acidic glycine buffer. Binding assays were used to identify eluted fractions containing the highest concentrations of receptor(s) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Proteins present in fraction (F)#5 (positive experimental fraction) and F#9 (negative control fraction) were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and differential protein bands were subjected to in tandem mass spectrometry fragmentation (LS-MS/MS) for protein identification (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Notably, immunoblotting of eluted fractions revealed the presence of two vitamin D-binding receptor candidates: protein disulfide-isomerase A3 (PDIA3; also known as glucose-regulated protein-58 kDa, GRP58; endoplasmic reticulum protein of 57 kDa, ERp57; and membrane-associated rapid response to steroid-binding, 1,25D<sub>3</sub>-MARRS) (<xref ref-type="bibr" rid="bib24">Khanal and Nemere, 2007</xref>; <xref ref-type="fig" rid="fig1">Figure 1E</xref>, top panel) and vitamin D-binding protein (DBP) (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, bottom panel). In vitro binding assays to recombinant PDIA3 and DBP confirmed preferential binding of CSSTRESAC-phage relative to the negative control insertless phage (<xref ref-type="fig" rid="fig1">Figure 1F</xref>).</p></sec><sec id="s2-2"><title>CSSTRESAC mimics active vitamin D</title><p>PDIA3 and DBP both bind to vitamin D (<xref ref-type="bibr" rid="bib8">Christakos et al., 2016</xref>), thereby suggesting that CSSTRESAC might be structurally similar to vitamin D. Thus, we applied computational molecular modeling to determine whether the peptide CSSTRESAC would show conformational similarities to vitamin D (<xref ref-type="fig" rid="fig1">Figure 1G–J</xref>). The structure of CSSTRESAC was modeled with a de novo peptide structure prediction tool (PEP-FOLD2) (<xref ref-type="bibr" rid="bib40">Shen et al., 2014</xref>; <xref ref-type="fig" rid="fig1">Figure 1G</xref>). Next, Rosetta FlexPepDock (<xref ref-type="bibr" rid="bib38">Raveh et al., 2011</xref>) was used to identify putative binding site(s) for CSSTRESAC on the surface of DBP. Because the 3D structure of the DBP/1,25-(OH)<sub>2</sub>D<sub>3</sub> complex was not available when this work was performed, we used a 2.3 Å-resolution X-ray crystal structure of the unliganded form of human DBP (PDB ID: 1KW2_A) (<xref ref-type="bibr" rid="bib32">Otterbein et al., 2002</xref>). To initiate the docking calculation, CSSTRESAC was pre-positioned in the vicinity of the known binding site for 25-(OH)D<sub>3</sub>, [and likely 1,25-(OH)<sub>2</sub>D<sub>3</sub> based on previous computational modeling], visualized in the 2.1 Å-resolution X-ray crystal structure of a liganded form of human DBP (PDB ID: 1J78) (<xref ref-type="bibr" rid="bib46">Verboven et al., 2002</xref>). The molecule 25-(OH)D<sub>3</sub>, also known as calcidiol, binds at the base of a deep, largely hydrophobic pocket on the surface of domain I of DBP (<xref ref-type="fig" rid="fig1">Figure 1J</xref>). The computed model of the DBP/CSSTRESAC complex revealed a potential binding site for CSSTRESAC at the opening of the hydrophobic pocket. The computed model suggests that the largely hydrophilic peptide interacts with two superficial residues adjacent to the hydrophobic pocket, including Glu24 and Lys51 (<xref ref-type="fig" rid="fig1">Figure 1H,I</xref>; <xref ref-type="bibr" rid="bib46">Verboven et al., 2002</xref>). The outcome of the Rosetta FlexPepDock calculations suggests that although CSSTRESAC binds at a similar site on the surface of DBP as 1,25-(OH)<sub>2</sub>D<sub>3</sub> and its metabolite calcidiol, it is unlikely to interact more tightly and should be competitively displaced by the natural ligands of the receptor protein (<xref ref-type="fig" rid="fig1">Figure 1I,J</xref>). Indeed, experimental binding of CSSTRESAC-phage to immobilized DBP was reduced (Student’s <italic>t</italic>-test, p&lt;0.05) by increasing amounts of 1,25-(OH)<sub>2</sub>D<sub>3</sub> but not by the non-active precursor vitamin D<sub>3</sub> (<xref ref-type="fig" rid="fig1">Figure 1K</xref>), a biochemical finding consistent with the computational model.</p></sec><sec id="s2-3"><title>PDIA3 is a receptor of the CSSTRESAC peptide and a novel molecular marker of TAM</title><p>Despite the fact that binding of CSSTRESAC to DBP is strongly suggested by our structural modeling, DBP is a circulating serum protein and thus unlikely to function as an integral cell surface receptor. Therefore, we reasoned that the membrane-bound receptor candidate PDIA3 would likely be the cell surface receptor on TAM responsible for the binding of CSSTRESAC. To determine whether PDIA3 is present on the cell surface of TAM in TNBC, we co-stained CD11b<sup>+</sup> TAM isolated from EF43.<italic>fgf4</italic> tumors with antibodies against IL-10, IL-12, and PDIA3. Flow cytometry analysis showed robust expression of PDIA3 on the surface of CD11b<sup>+</sup>IL-10<sup>high</sup>IL-12<sup>low</sup> TAM (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), identifying PDIA3 as a new cell membrane-associated candidate marker of M2-polarized macrophages. Consistently, EF43.<italic>fgf4</italic> cells isolated from tumors did not express PDIA3 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), in agreement with the lack of CSSTRESAC-phage binding to EF43.<italic>fgf4</italic> cells. Moreover, immunofluorescence staining of frozen breast tumor sections from tumor-bearing mice receiving CSSTRESAC-phage iv suggested co-localization between PDIA3 and CD68, a well-established cell surface marker of macrophages (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>). Finally, administration of an anti-PDIA3 antibody into EF43.<italic>fgf4</italic> tumor-bearing mice confirmed accessibility of PDIA3 through the systemic circulation (<xref ref-type="bibr" rid="bib33">Ozawa et al., 2008</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Notably, extracellular expression of PDIA3 was largely restricted to resident macrophage in tumors, while control tissues showed minimal cell surface staining. The macrophage marker F4/80 served as an additional positive control (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>PDIA3 is present on the surface of TAM.</title><p>(<bold>A</bold>) FACS analysis of total TAM isolated from EF43.fgf4-derived mammary tumors shows high levels of PDIA3 expression in a subpopulation of F4/80<sup>+</sup>CD11b<sup>+</sup>IL10<sup>high</sup>IL12<sup>low</sup> TAM. (B) EF43.fgf4 cells do not express detectable levels of PDIA3 on their surface. (<bold>C-D</bold>) PDIA3 expression in TAM and co-localization with the pan-macrophage marker CD68 as detected by immunofluorescence of tumor tissue sections from tumor-bearing mice administered iv with anti-PDIA3 antibody (<bold>C</bold>) or CSSTRESAC-phage (<bold>D</bold>). (<bold>E-G</bold>) Purified TAM from EF43.fgf4 mammary tumors were established in culture and treated with either the soluble CSSTRESAC peptide, 1,25-(OH)<sub>2</sub>D<sub>3</sub>, or both. Controls included untreated cells, and cells treated with vehicle. Expression of anti-inflammatory (<bold>E</bold> and <bold>G</bold>) or pro-inflammatory (<bold>F</bold> and <bold>G</bold>) cytokines in CD11b<sup>+</sup>F4/80<sup>+</sup> TAM was assessed by quantitative real-time PCR. Graphics represent expression fold-change relative to control cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>PDIA3 is accessible through the systemic circulation.</title><p>(<bold>A</bold>) An anti-PDIA3 antibody was administered iv into EF43.fgf4 tumor-bearing mice and was allowed to circulate for 5 min in deeply anesthetized mice before whole body perfusion through the heart. The anti-PDIA3 antibody preferentially targeted the tumor, indicating that PDIA3 is systemically accessible. (<bold>B</bold>) The F4/80 pan-macrophage marker was used as a positive control for TAM identification. (<bold>C</bold>) TAM isolated from EF43.fgf4 mammary tumors were established in culture and treated with the soluble CSSTRESAC peptide, 1,25-(OH)<sub>2</sub>D<sub>3</sub>, or both. Expression of cytokine genes was evaluated by quantitative real-time PCR. Graphics represent expression fold change relative to untreated cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>CSSTRESAC mimics active vitamin D, binds to DBP and mediates activation of PDIA3 on the surface of TAM</title><p>To gain insight into the biological mechanisms associated with this newly discovered ligand-receptor system, we next evaluated whether the predicted interactions between CSSTRESAC and PDIA3 on the surface of TAM would have functional consequences. We isolated CD11b<sup>+</sup>F4/80<sup>+</sup> TAM from EF43.<italic>fgf4</italic> mammary tumors, established them in culture (&gt;99% purity by FACS), and tested cytokine production as a surrogate for immunoregulatory responses upon treatment (<xref ref-type="fig" rid="fig2">Figure 2E–G</xref>). Cytokines were measured by real-time quantitative PCR after RNA extraction from cultured CD11b<sup>+</sup>F4/80<sup>+</sup> TAM exposed to soluble CSSTRESAC. Untreated cultured CD11b<sup>+</sup>F4/80<sup>+</sup> TAM served as negative controls. Treatment of CD11b<sup>+</sup>F4/80<sup>+</sup> TAM with the soluble CSSTRESAC peptide induced a marked (on average ~40 fold) increase in gene expression of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6 (<xref ref-type="fig" rid="fig2">Figure 2F,G</xref>). In contrast, there was much lower increases in gene expression of the anti-inflammatory cytokines TGF-β1, TGF-β2, IL-10, and arginase-1 (<xref ref-type="fig" rid="fig2">Figure 2E–G</xref>) with IL-4 and IL-13 being undetectable. iNOS<sub>2</sub> (~20-fold) and the cytokine IL-23 (~10-fold) were also substantially increased upon exposure to CSSTRESAC. IL-18, IL-12, and INFγ showed modest increases or were detected only at background levels (<xref ref-type="fig" rid="fig2">Figure 2F,G</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). This cellular response was abrogated when CSSTRESA-treated CD11b<sup>+</sup>F4/80<sup>+</sup> TAM were co-treated with 1,25-(OH)<sub>2</sub>D<sub>3</sub> (<xref ref-type="fig" rid="fig2">Figure 2F,G</xref>), verifying that it was specifically caused by the binding of the CSSTRESAC peptide. Thus, binding of CSSTRESAC directly to TAM may alter the local antitumor immune response through changes in cytokine production.</p></sec><sec id="s2-5"><title>Targeted ablation of PDIA3-expressing TAM affects tumor growth</title><p>We next investigated the biological significance and potential therapeutic effects of CSSTRESAC in the EF43.<italic>fgf4</italic> tumor model (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Mice bearing size-matched EF43.<italic>fgf4</italic> tumors were treated iv with soluble CSSTRESAC peptide, unrelated control peptide, or vehicle. A significant delay in tumor growth of mice treated with CSSTRESAC was observed as soon as one-week post initiation of treatment, compared to tumors of mice receiving an unrelated control peptide or vehicle alone (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, t-test, p&lt;0.001). FACS analysis of CD11b<sup>+</sup>F4/80<sup>+</sup> TAM showed a reduction in the number of CD11b<sup>+</sup>IL10<sup>high</sup>IL12<sup>low</sup>PDIA3-expressing TAM in tumors from mice treated with soluble CSSTRESAC peptide as compared to the negative control groups (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Immunohistochemistry staining of representative tumor sections further demonstrated a reduction of the macrophage population in tumors treated with soluble CSSTRESAC (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Thus, treatment of tumors with the soluble CSSTRESAC peptide inhibited tumor growth and altered the TAM population in tumors, which supports it as a potential antitumor drug lead candidate.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Targeted therapy delays growth of EF43.fgf4-derived mammary tumors.</title><p>(<bold>A</bold>) Therapeutic effect of systemic treatment of EF43.fgf4 tumor-bearing mice with soluble CSSTRESAC peptide (n = 10 each experimental cohort, details in Materials and methods). An unrelated control peptide and vehicle served as negative controls. Tumor sizes were measured by digital caliper 1 week after treatment initiation, and every other day afterwards. *** represents p&lt;0.001. (<bold>B</bold>) Treatment of tumor-bearing mice with CSSTRESAC reduces the number of PDIA3-expressing TAM (F4/80<sup>+</sup>CD11b<sup>+</sup>IL<sup>-</sup>10<sup>high</sup>IL-12l<sup>ow</sup>PDIA3<sup>+</sup>). The TAM population is represented as percentage of total non-malignant cells, as determined by flow cytometry. (<bold>C</bold>) Gene therapy with CSSTRESAC-AAVP-<italic>HSVtk</italic> plus GCV delays tumor growth. Mice cohorts with size-matched EF43.fgf4 mammary tumors received a single systemic iv administration of targeted CSSTRESAC-AAVP-<italic>HSVtk</italic> (5 × 10<sup>10</sup> TU) or control fd-AAVP-<italic>HSVtk</italic>. Mice received daily doses of GCV (80 mg/kg/day) starting at day 7 post AAVP-<italic>HSVtk</italic> administration until the end of the experiment. * represents p&lt;0.05. (<bold>D</bold>) Flow cytometry confirms reduction of F4/80<sup>+</sup>CD11b<sup>+</sup>IL-10<sup>high</sup>IL-12l<sup>ow</sup>PDIA3<sup>+</sup> TAM in tumors from CSSTRESAC-AAVP-<italic>HSVtk</italic>-treated mice. (<bold>E</bold>) Cytokine production by macrophages from tumors of mice treated with CSSTRESAC-AAVP-<italic>HSVtk</italic> or control groups. * represents p&lt;0.05. Results are reported as expression fold-change relative to control group (set to 1).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>CSSTRESAC peptide targets macrophage in vivo.</title><p>(<bold>A</bold>) FACS analysis confirming reduction of F4/80<sup>+</sup>CD11b<sup>+</sup>IL-10<sup>high</sup>IL-12<sup>low</sup>PDIA3<sup>+</sup> TAM in the CSSTRESAC-treated cohort, compared to a negative control cohort (n = 8 tumor-bearing mice per cohort). (<bold>B</bold>) CD163 expression in tumor tissue sections showing reduced number of monocytes and macrophages in mice treated with soluble CSSTRESAC compared to a control peptide.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Heat-map representing a more extensive cytokine profile of F4/80<sup>+</sup>CD11b<sup>+</sup>IL-10<sup>high</sup>IL-12l<sup>ow</sup>PDIA3<sup>+</sup> TAM isolated from tumors of treated and control groups.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig3-figsupp2-v1.tif"/></fig></fig-group><p>As an additional medical application, we also analyzed the use of CSSTRESAC as a theranostic ligand for targeting transgenes directly to tumors in preclinical settings. We engineered adeno-associated/phage (AAVP) (<xref ref-type="bibr" rid="bib14">Dobroff et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">Ferrara et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Hajitou et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Smith et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Staquicini et al., 2011</xref>) constructs carrying the <italic>Herpes simplex virus thymidine kinase</italic> (<italic>HSVtk</italic>) gene to enable targeted suicide therapy upon combination with the pro-drug ganciclovir (GCV) (<xref ref-type="bibr" rid="bib14">Dobroff et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">Ferrara et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Hajitou et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Smith et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Staquicini et al., 2011</xref>; <xref ref-type="bibr" rid="bib45">Tjuvajev et al., 1998</xref>). CSSTRESAC-AAVP-<italic>HSVtk</italic> or control AAVP lacking the targeting peptide (fd-AAVP-<italic>HSVtk</italic>) were delivered to cohorts of size-matched EF43.<italic>fgf4</italic> tumor-bearing mice. Animals treated with vehicle were used as controls (n = 10, each cohort). All cohorts received GCV. By the end of the experiment, the sizes of tumors in mice that received CSSTRESAC-AAVP-<italic>HSVtk</italic> were significantly smaller than that of mice receiving control fd-AAVP-<italic>HSVtk</italic> or vehicle alone (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, t-test, p&lt;0.001). Moreover, macrophage quantification showed a reduction in the number of F480<sup>+</sup>CD11b<sup>+</sup>IL10<sup>high</sup>IL12<sup>low</sup>PDIA3-expressing TAM (<xref ref-type="fig" rid="fig3">Figure 3D</xref>) accompanied by a shift in the cytokine profile toward an inflammatory response in the tumor microenvironment (<xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>).</p><p>The preclinical efficacies of soluble CSSTRESAC peptide and of CSSTRESAC-AAVP-<italic>HSVtk</italic> were further investigated in silico. We have conceived a mathematical model of tumor growth and treatment efficiency to predict response in breast cancer patients. This mechanistic model was formulated as a system of ordinary differential equations based on our prior work on modeling cancer response to various forms of drug treatment (<xref ref-type="bibr" rid="bib5">Brocato et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Brocato et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Dogra et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Goel et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Wang et al., 2016</xref>). The model accounts for two primary opposing processes: tumor cell growth and death caused by the CSSTRESAC peptide, while also allowing for competitive antagonism exhibited by 1,25-(OH)<sub>2</sub>D<sub>3</sub> in serum. To model tumor growth delay in gene therapy experiments, an extra death rate term was introduced that characterizes death due to GCV activated through <italic>HSVtk</italic> (equations are described in Materials and methods). Model predictions corroborated with experimental data from mouse models (Pearson correlation coefficient <inline-formula><mml:math id="inf1"><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.998</mml:mn></mml:math></inline-formula>, p = 0.001) and were used to simulate a clinical trial for treatment of breast cancer patients with soluble CSSTRESAC (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). To evaluate the importance of a possible competitive binding between 1,25-(OH)<sub>2</sub>D<sub>3</sub> and soluble CSSTRESAC in the serum, the dissociation constant <inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> was perturbed by ± 20% of the reference parameter value. As such, an increase in <inline-formula><mml:math id="inf3"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> would reflect the competitive binding of the antagonist 1,25-(OH)<sub>2</sub>D<sub>3</sub>, where the dissociation of CSSTRESAC from PDIA3 on the cell surface increases and the antitumor effects of CSSTRESAC decreases. Similarly, a reduced <inline-formula><mml:math id="inf4"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> would reflect a stronger binding between CCSTRESAC and PDIA3 with the consequent inhibition of tumor growth (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). We have also considered a hypothetical experiment in patients where a constant rate of i.v. infusion of the soluble CSSTRESAC peptide was compared to the efficacy of a unit i.v. bolus. Our mathematical model predicted that infusion of CCSTRESAC would result in ~400 mm<sup>3</sup> greater reduction in tumor volume compared to bolus (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Our proposed working hypothesis shows that the CSSTRESAC-DBP complex specifically binds to PDIA3 and elicits functional changes in PDIA3-expressing TAM within the tumor microenvironment. Such biochemical and cellular alterations may in turn result in an inflammatory local response potentially mediated by IL-6, IL-1β, and TNF-α, and inhibition of tumor growth (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Mechanistic mathematical model of tumor growth inhibition upon treatment with soluble CSSTRESAC and competitive antagonism by 1,25-(OH)<sub>2</sub>D<sub>3</sub>.</title><p>(<bold>A</bold>) System interactions captured by a mechanistic mathematical model. Upper panel shows the non-linear regression of the tumor growth model upon treatment of tumor-bearing mice with soluble CSSTRESAC. Error bar represents mean ± standard deviation (S.D.) of the data shown in <xref ref-type="fig" rid="fig3">Figure 3A</xref>. Lower panel shows the projected temporal evolution of the tumor volume without infusion (μ = 0) and with infusion (μ = 0.75) in a simulated human clinical trial. (<bold>B</bold>) A schematic representation of the working hypothesis. The complex CSSTRESAC-DBP binds PDIA3 and eliminates PDIA3-expressing TAM from the tumor microenvironment (through an unknown mechanism), resulting in a pro-inflammatory local response and inhibition of tumor growth. Because 1,25-(OH)<sub>2</sub>D<sub>3</sub> may compete out the effects of CSSTRESAC, binding to PDIA3-expressing TAM in the presence of 1,25-(OH)<sub>2</sub>D<sub>3</sub> may be abrogated, and tumor cells can continue to grow.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Mathematical modeling of CSSTRESAC peptide distribution in tumor-bearing mice.</title><p>(<bold>A</bold>) Change in tumor volume with respect to the reference volume versus the dissociation constant Kd. (<bold>B</bold>) Peptide concentration kinetics without infusion (μ = 0) and with infusion (μ = 0.75). (<bold>C</bold>) Numerical results of tumor growth model corresponding to <xref ref-type="fig" rid="fig3">Figure 3c</xref>. Error bars represent mean ±S.D. of the data shown in <xref ref-type="fig" rid="fig3">Figure 3c</xref>. (<bold>D</bold>) Schematic of one-compartment pharmacokinetic model following (left panel) iv administration of peptide or AAVP-peptide, and (right panel) ip administration of GCV.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Lastly, we searched a publicly available single-cell transcriptome dataset of breast cancer and immune-infiltrating cells containing data from TNBC patients for PDIA3-expressing TAM. Transcripts per million reads (TPM), single-cell (sc)RNA-seq and sample information were obtained from the Gene Expression Omnibus (GEO) repository (accession #GSE75688) (<xref ref-type="bibr" rid="bib9">Chung et al., 2017</xref>); an initial gene set variation (GSVA) analysis extracted single cells (n = 35) displaying gene expression pathways of infiltrating macrophages. Expression of the <italic>PDIA3</italic> gene in these cells was deemed high, medium, or low, and it was clustered/plotted relative to the expression of established markers of immune suppression and M2-polarized macrophages (<italic>IL10</italic>, <italic>TGFB1</italic>, <italic>CD274</italic>, <italic>PDCD1LG2</italic>, <italic>CD68</italic>, <italic>CD163</italic>, <italic>ITGAM</italic>, <italic>CXCL2</italic>, and <italic>MS4A6A</italic>). Markers of angiogenesis and/or disease progression (<italic>PLAUR</italic>, <italic>IL8</italic>, <italic>VEGFA</italic>, and <italic>MMP9</italic>) were also included (<xref ref-type="bibr" rid="bib17">Garrido-Castro et al., 2019</xref>; <xref ref-type="bibr" rid="bib11">DeNardo and Ruffell, 2019</xref>; <xref ref-type="bibr" rid="bib25">Lim et al., 2018</xref>; <xref ref-type="bibr" rid="bib47">Wagner et al., 2019</xref>). An unsupervised clustering analysis (<xref ref-type="fig" rid="fig5">Figure 5</xref>) showed that high levels of <italic>PDIA3</italic> expression in TAM clustered positively with markers of M2-polarized TAM as well as poor prognosis indicators and genes associated with immune suppression. These genomic results support the presence of PDIA3-expressing TAM in human TNBC, and suggest that these preclinical findings may be clinically meaningful.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Heat-map of PDIA3 gene expression in pre-defined myeloid cells from human TNBC.</title><p>The heat map shows a strong association with the expression of genes characteristic of M2-polarized macrophage, markers of immunosuppression and angiogenesis (i.e. poor prognosis). The yellow box highlights cells with the highest expression of PDIA3.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65145-fig5-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We report that PDIA3 is a functional receptor expressed on the cell surface of the M2-like class of TAM in TNBC. We show that PDIA3, an established vitamin D-interacting protein, has immunoregulatory functions as the TAM cell surface receptor for the peptide CSSTRESAC, with clear effects in preclinical non-TNBC and TNBC mouse models and, at least potentially, in TNBC patients. The effects of soluble CSSTRESAC and CSSTRESAC-AAVP-<italic>HSVtk</italic> in the local and systemic immune responses in murine models of breast cancer also suggest that combination therapy with immunomodulators may increase the therapeutic response against highly inflammatory tumors. In particular, TNBCs are more likely to respond to immunotherapy due to higher numbers of tumor-infiltrating lymphocytes, higher levels of PD-L1 expression in both tumor cells and immunce cells as well as a higher mutational burden and the consequent rise in tumor-specific neo-antigens. Therefore, immunomodulation of the local and/or systemic responses with immune checkpoint inhibitors could—at least in theory—be amplified by CSSTRESAC-mediated immunoregulatory functions in breast cancer, as well as other TAM-infiltrated cancers, and might perhaps become a medically meaningful translational strategy. In this setting, CSSTRESAC could also be considered as a new non-steroidal vitamin D analogue prototype for drug lead-optimization, with applications that may include other diseases (malignant or non-malignant) with an inflammatory component.</p><p>Finally, we introduce a ligand-directed AAVP-<italic>HSVtk</italic> platform for theranostics based on cell surface targeting of PDIA3 along with a mathematical model that reproduces the experimental dataset and estimates CSSTRESAC treatment outcomes in breast cancer. These observations in vitro, in mouse mammary tumor models, plus an initial in silico analysis of cells from TNBC patients, support an unrecognized regulatory role of PDIA3-expressing TAM in the tumor immune response. Finally, one should note that our mathematical model shows that native competing serum 1,25-(OH)<sub>2</sub>D<sub>3</sub> is unlikely to influence the binding of CSSTRESAC to its target on TAM. Notably, the Human Protein Atlas shows cytoplasmic expression of PDIA3 in human breast cancer cells. Thus, expression of PDIA3 on the surface of cancer cells, and potential effects of the direct binding of CSSTRESAC to breast cancer cells warrants further investigation and, if confirmed, might have translational implications in the setting of TNBC, and other human tumors or even non-malignant disorders with a inflammatory component. Similarly, drug interactions caused by prolonged exposure to CSSTRESAC in the presence of steroids—which are often used in cancer patients—might confound the investigational use of CSSTRESAC-based therapies and should be carefully considered.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Antibodies and recombinant proteins</title><p>Anti-PDIA3, anti-IL-10, anti-IL-12, and anti-F4/80 were purchased from BD Pharmingen and were used in flow cytometry and immunofluorescence. Immunoblottings were performed with antibodies purchased from Sigma (Glutathione S-transferase, PDIA3 and DBP), Abcam (ER), Cell Signaling (PgR), and R and D Systems (HER2). Taqman assays for real-time PCR quantification of cytokines were purchased from Applied Biosystems. Recombinant proteins (DBP and PDIA3), cholecalciferol and calcitriol were all acquired from Abcam. Fluorescence-conjugated secondary antibodies were purchased from Jackson Immunoresearch. Peptides were custom synthesized by PolyPeptide Laboratories to our specifications (&gt;95% purity).</p></sec><sec id="s4-2"><title>Cells lines and tissue culture</title><p>Mouse mammary EF43.<italic>fgf4</italic> cells (<xref ref-type="bibr" rid="bib1">Adams et al., 1987</xref>; <xref ref-type="bibr" rid="bib21">Hajitou et al., 1998</xref>) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 5 ng/ml mouse epithelial growth factor (EGF), 1 μg/ml bovine insulin, and antibiotics. MDA-MB-231 cells (<xref ref-type="bibr" rid="bib7">Cailleau et al., 1974</xref>) were obtained from the American Type Culture Collection (ATCC) and were grown as a monolayer in RPMI 1640 medium supplemented with 8.25% FBS. Cells were maintained at 37°C and 5% CO<sub>2</sub>. All cells were routinely tested for the presence of mycoplasm. ATCC garantees the identity of purchased cells.</p></sec><sec id="s4-3"><title>Animals and experimental tumor models</title><p>Eight-week-old female nude (nu/nu) mice and immunocompetent BALB/c mice were housed in the animal facilities of the University of Texas M.D. Anderson Cancer Center # 11-99-09935 and Rutgers University New Jersey Medical School (PROTO201800055), all in the USA. Polyoma middle T transgenic (PyMT) mice were maintained at the University Medical Center Hamburg-Eppendorf, Germany. All animal procedures were reviewed and approved by the corresponding Institutional Animal Care and Use Committee (IACUC)-equivalent at each institution.</p><p>Both human MDA-MB-231 cells and mouse EF43.<italic>fgf4</italic> cells were implanted in the mammary fat pads of nude and immunocompetent BALB/c mice, respectively. Tumor-bearing mice were sorted into experimental size-matched cohorts when established tumors reached ~200 mm<sup>3</sup>. These procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication #85–23, revised 1996) approved by the local ethics review board.</p><p>PyMT [strain FVB/N-TgN (MMTVPyVT)634-Mul] (<xref ref-type="bibr" rid="bib30">Michelfelder et al., 2009</xref>) were obtained from Jackson Laboratory (Bar Harbor, ME, USA). All procedures involving PyMT mice were conducted in accordance with the German Animal Protection Code and approval was granted by the local ethics review board (Hamburg, Germany). PyMT transgenic mice genotyping was performed through blood samples collected from the retrobulbar venous plexus under anesthesia (2% isoflurane, 98% oxygen), as described (<xref ref-type="bibr" rid="bib30">Michelfelder et al., 2009</xref>).</p><p>Treatment of tumor-bearing mice with a single-dose of CSSTRESAC-AAVP-HSV<italic>tk</italic> or control fd-AAVP-HSV<italic>tk</italic> (5 × 10<sup>10</sup> TU per mouse) was followed by daily intraperitoneal (ip) administrations of GCV at 80 mg/kg/day. Tumor sizes were measured every-other day with a digital caliper and plotted as tumor volume (mm<sup>3</sup>).</p></sec><sec id="s4-4"><title>Phage display methodology</title><p>The Biopanning and Rapid Analysis of Selective Interactive Ligands (BRASIL) methodology (<xref ref-type="bibr" rid="bib18">Giordano et al., 2001</xref>) was used to test binding of phage to cultured cells. For phage binding to the candidate receptors PDIA3 and DBP, individual microtiter wells of 96-well plates were coated overnight (ON) with 1 μg/ml of recombinant proteins, followed by blocking with BSA and incubation with 10<sup>9</sup> TU of insertless phage or CSSTRESAC-phage for 1 hr at room temperature (RT). GST and BSA were used as control proteins. Bound phage were recovered by log-phase infection of host bacteria (200 μl <italic>E. coli</italic> K91Kan). Competitive binding of CSSTRESAC-phage and 1,25-(OH)<sub>2</sub>D<sub>3</sub> to DBP was performed by using the same experimental protocol. Competition was performed in wells pre-incubated with 3 nM or 30 nM of either 1,25-(OH)<sub>2</sub>D<sub>3</sub> or cholecalciferol.</p><p>Combinatorial phage display selections in vivo in tumor-bearing mice were performed as described (<xref ref-type="bibr" rid="bib14">Dobroff et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">Ferrara et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Hajitou et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Smith et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Staquicini et al., 2011</xref>; <xref ref-type="bibr" rid="bib2">Arap et al., 1998</xref>; <xref ref-type="bibr" rid="bib28">Marchiò et al., 2004</xref>; <xref ref-type="bibr" rid="bib35">Pasqualini and Ruoslahti, 1996</xref>). In brief, animals received 10<sup>9</sup> TU iv of an unselected phage display random peptide library (displaying the insert CX<sub>7</sub>C). Tumors and control organs were collected after 24 hr of systemic circulation. For homing of individual phage clones in vivo, tumor-bearing mice were deeply anesthetized with 1–2% isofluorane and received 10<sup>9</sup> TU of targeted phage or insertless control phage, both administered iv side-by-side. Phage particles were recovered from tissue samples by bacterial infection and processed as described (<xref ref-type="bibr" rid="bib14">Dobroff et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">Ferrara et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Hajitou et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Smith et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Staquicini et al., 2011</xref>; <xref ref-type="bibr" rid="bib2">Arap et al., 1998</xref>; <xref ref-type="bibr" rid="bib28">Marchiò et al., 2004</xref>; <xref ref-type="bibr" rid="bib35">Pasqualini and Ruoslahti, 1996</xref>).</p></sec><sec id="s4-5"><title>Peptide affinity chromatography</title><p>Receptor candidates were isolated by using an affinity chromatography CarboxyLink column (ThermoFisher Scientific) conjugated with the synthetic CSSTRESAC peptide. Protein extracts (10 mg/purification) were added to peptide conjugated columns and incubated ON at 4°C under constant gentle agitation. After extensive washes, bound proteins were eluted with an excess of soluble CSSTRESAC peptide followed by elution in low pH glycine buffer. Contaminants including detergents, salts, lipids, phenolics, and nucleic acids were removed through a 2-D clean-up kit from GE Healthcare Life Sciences. Proteins were re-suspended in rehydration buffer (8 M urea, 2% CHAPS, 40 mM DTT, 0.5% IPG buffer, 0.002% bromophenol blue) and 2-D gel electrophoresis was performed by using the ZOOM IPGRunner System (Life Technologies). The final gel was stained with SYPRO Ruby Protein Gel Stain (Life Technologies) and imaged in a 300 nm ultraviolet transilluminator. Unique bands were excised from the SDS gels and digested with trypsin. LC-MS/MS analysis was performed at the Proteomics Core Facility of the University of Texas M.D. Anderson Cancer Center.</p><p>To test purified fractions for the presence of candidate receptors, control and experimental fractions were immobilized on individual microtiter wells of 96-well plates ON at 4°C. Wells were blocked with phosphate-buffered saline (PBS) containing 3% BSA for 1 hr at RT and incubated with 10<sup>9</sup> TU of insertless phage or CSSTRESAC-phage. After extensive washing with PBS, bound phage particles were recovered by infection of host bacteria.</p></sec><sec id="s4-6"><title>Peptide structure prediction and docking</title><p>The peptide sequence of CSSTRESAC was entered into PEP-FOLD2 (<xref ref-type="bibr" rid="bib40">Shen et al., 2014</xref>) with a designated disulfide bridge between Cys1 and Cys9 (to ensure the cyclic peptide configuration) and 100- and 200-run simulations were applied. The best-fit model containing a disulfide bridge between Cys1 and Cys9 based on sOPEP energy (i.e. the negative value with greatest absolute value) was selected as the structure for further experimentation. By using the UCSF Chimera (<xref ref-type="bibr" rid="bib37">Pettersen et al., 2004</xref>), a PDB file with CSSTRESAC positioned adjacent to human DBP (PDB ID: 1KW2_A) (<xref ref-type="bibr" rid="bib32">Otterbein et al., 2002</xref>) in roughly the same location as 25-(OH)D<sub>3</sub> in its complex with human DBP (PDB ID: 1J78) (<xref ref-type="bibr" rid="bib46">Verboven et al., 2002</xref>) was generated and inputted into Rosetta FlexPepDock (<xref ref-type="bibr" rid="bib38">Raveh et al., 2011</xref>). The top generated model according to energy scoring, a revised version of Rosetta full-atom and coarse-grained energy functions, with CSSTRESAC bound to the same binding pocket as 25-(OH)D<sub>3</sub> was selected for analysis. Interacting residues of CSSTRESAC and DBP were analyzed via UCSF Chimera (<xref ref-type="bibr" rid="bib37">Pettersen et al., 2004</xref>).</p></sec><sec id="s4-7"><title>Immunohistochemistry, immunofluorescence, and flow cytometry</title><p>For immunohistochemistry and immunoflorescence, the anti-PDIA3 antibody was administered iv into the tail vein of EF43.<italic>fgf4</italic> tumor-bearing BALB/c mice. After 5 min, the mice were killed and perfused through the heart. Tumors and control organs were collected and either quickly-frozen in liquid nitrogen or preservative-fixed, and paraffin-embedded (<xref ref-type="bibr" rid="bib14">Dobroff et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">Ferrara et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Hajitou et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Smith et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Staquicini et al., 2011</xref>; <xref ref-type="bibr" rid="bib2">Arap et al., 1998</xref>; <xref ref-type="bibr" rid="bib28">Marchiò et al., 2004</xref>; <xref ref-type="bibr" rid="bib35">Pasqualini and Ruoslahti, 1996</xref>). The presence of the anti-PDIA3 antibody in tissue sections was verified by detection with a secondary antibody conjugated to horseradish peroxidase (HRP) or were stained for the presence of macrophages with an anti-CD68 antibody conjugated to FITC. For flow cytometry, whole EF43.<italic>fgf4</italic> tumors were dissected out from tumor-bearing BALB/c mice and single-cell suspensions were prepared by tumor mincing. The single-cell suspension was washed with PBS containing 5% FBS and 0.01% NaN<sub>3</sub>. Cell suspensions were aliquoted into 12 × 75 mm flow cytometry tubes as 5 × 10<sup>5</sup> cells per tube and ice-cold incubated for 15 min with an Fc receptor blocking agent, followed by antibodies against PDIA3, F4/80, IL-10, and IL-12. Cells were incubated on ice for 30 min, followed by washes and secondary antibodies.</p></sec><sec id="s4-8"><title>Quantitative real-time PCR</title><p>Three sets of total RNA (RNeasy Mini Kit, Qiagen) were independently isolated from cultured macrophages, or fresh macrophages isolated directly from tumors. DNA synthesis was performed with the GoScript Reverse Transcription System (Promega) by using oligodT for reverse transcription. Gene expression was analyzed with the use of Taqman probes (Applied Biosystems) in a 7500 Fast Real-Time PCR System instrument (Applied Biosystems) and three sets of endogenous control genes: 18S and GAPDH and GUSB1.</p></sec><sec id="s4-9"><title>Macrophage isolation and tissue culture</title><p>TAM were obtained directly from EF43.<italic>fgf4</italic> tumors. Tissue digestion was performed in collagenase A in serum-free DMEM (1 mg/mL) for 20 min at 37°C, followed by filtering through 70 μm nylon cell strainers and centrifugation. Macrophages were enriched by magnetic bead separation of CD11b-positive cells (Miltenyi Biotec) and either used for RNA extraction or cultured in 6-well plates containing DMEM (Gibco) supplemented with 20% FBS (Sigma) and 50 ng/ml of M-CSF (R and D Systems). A homogeneous population of adherent macrophages (namely,&gt;99% CD11b<sup>+</sup>F480<sup>+</sup>) was obtained after 7 days in culture.</p></sec><sec id="s4-10"><title>Preparation and characterization of liposomes</title><p>Cationic lipids DOTAP, DOPE, 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide] (DOPE-MPB), and DOPE-rhodamine B were purchased from Avanti Polar Lipids. Gadolinium (Gd)-BOA was commercially obtained (Gateway Chemical Technology). Liposomes were prepared by lipid hydration. DOTAP:DOPE:DOPE-MPB (1:0.95:0.05, mol/mol/mol) and were dissolved in chloroform in a round-bottom flask. DOPE-rhodamine B at a concentration of 0.2 mol was included for visualization of liposomes by high-resolution fluorescence microscopy. The total concentration of lipids was determined after extrusion by using the erythrosine method and found to be 10 mg/ml. Gd-BOA (25 mol %) was added to the base formulation in place of different molar fraction of DOTAP. The solvent was removed by evaporation by using nitrogen flow and the lipid film was hydrated by 5% dextrose solution. After hydration, the liposomes were left under an argon blanket at 4°C ON to allow annealing and 24 hr later the suspension of lipids was vortexed for 5 to 10 min, to allow liposome formation, and passed through a 200 nm pore size polycarbonate membrane through an extruder (Avestin Inc). The surface of liposomes was decorated with targeted and control peptides via maleimide chemistry. Fluorescein-labeled control peptide was synthesized by the Synthesis and Sequencing Facility of Johns Hopkins University School of Medicine. A total of 250 μg of either targeted or control peptide was added to the liposomal suspension and left for 24 hr at 4°C to allow covalent coupling. Subsequently, 300 μg of N-ethylmaleimide (NEM; Pierce) were added to the liposomal suspension and kept for 2 hr at RT to block free sulfhydryl groups. Uncoupled peptide and excess of NEM were separated by using Sephadex G-100 size exclusion chromatography.</p><p>The hydrodynamic diameters and ζ-potential of liposomes without peptides, liposomes with targeted peptide, or control peptide were measured in 10 mM NaCl at 25°C in two independent experiments in a Malvern Zetasizer (Malvern Inc). Each measurement was repeated at least three times. The total concentration of Gd-BOA incorporated within the lipid bi-layer was determined with inductively coupled plasma mass spectrometry (ICP-MS from Perkin Elmer). The hydrodynamic diameter of liposomes with targeted or control peptides was in the range 150–200 nm with polydispersity index less than 0.2 nm. The presence of either targeted or control peptides on the surface of liposomes did not affect size distribution, and suspensions of liposomes were stable for several months at 4°C. Additional characterization of these liposomes revealed a surface charge of 27.5 ± 2.6 mV for uncoupled liposomes, 26.2 ± 0.9 mV for targeted liposomes, and 24.3 ± 1.2 mV for control liposomes.</p></sec><sec id="s4-11"><title>Magnetic resonance imaging and optical imaging</title><p>Cohorts of female nu/nu mice (n = 21) were inoculated in the mammary fat pad with 2 × 10<sup>6</sup> MDA-MB-231 cells suspended in 50 μl of Hanks balanced salt solution (ThermoFisher Scientific). Prior to tumor implantation, T1 relaxation times of the liposomal solutions were measured on a 4.7 T Bruker Biospec spectrometer horizontal bore magnet (Bruker BioSpin GmBH) with an inversion recovery sequence (repetition time [TR] 2000 milliseconds, number of averages [NA] 1 and 10 relaxation delays of 5, 10, 15, 20, 40, 60, 80, 100, 400, 800 ms). MRI studies were performed when tumor sizes reached ~300–350 mm<sup>3</sup>. Multi-slice T1-weighted images were acquired with a multislice-spin echo (MSME) sequence (echo time [TE] 11.4 ms, TR 500 milliseconds, NA 2, field of view [FOV] 1.6 cm, matrix size 128 × 128, slice thickness 1 mm, from 6 to 8 slices). Quantitative T1 multi-slice maps with relaxation delays of 100, 500, 1000, and 7000 ms were obtained with TE 0.98 milliseconds, TR 500 ms, NA 8, FOV 1.6 cm, matrix size 128 × 128, slice thickness 1 mm with a modified SNAPSHOT FLASH sequence. The MRI scans were acquired before and at 3, 6, 24, 48, and 72 hr following iv administration of targeted or control liposomes. Images were processed by using customized analyses programs developed in Interactive Data Language (IDL; ITT Visual Information Solutions).</p><p>Biodistribution studies of Gd-BOA incorporated within lipid bi-layers of liposomes were performed on an 11.7 T wide-bore MR spectrometer (Bruker BioSpin GmBH) equipped with triple-axis gradients. T1 relaxation times of tumor, liver, kidney, spleen, lungs, intestine, heart, blood, and muscle (n = 3 each) were measured with an inversion recovery sequence (TR = 20 s, NA = 1 and 10 relaxation delays: 5, 10, 15, 20, 40, 60, 80, 100, 400, 800 ms for liver, spleen, and blood, and 40, 80, 100, 200, 400, 600, 1000, 5000, 8000, 10,000 milliseconds for triplicates of tumor, kidney, heart, lungs, and muscle). Biodistribution studies were also performed by using the fluorescent signal from rhodamine-labeled liposomes and FITC-labeled targeted or control peptide. Tumor-bearing mice (n = 3 in each group) received either targeted or control liposomes iv. Mice were killed at each time point and 1-mm-thick slices of tumor, liver, kidney, spleen, lungs, intestine, heart, and muscle were imaged in a Xenogen IVIS 200 optical imaging device (PerkinElmer).</p><p>To rule out hepatic toxicity associated to liposomal administration, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) assay kits were purchased from Pointe Scientific Inc Levels of ALT and AST in mice serum were measured 48 hr post iv administration of targeted liposomes, control liposomes, or vehicle-only.</p></sec><sec id="s4-12"><title>Mathematical model of tumor growth and treatment efficiency</title><p>We developed a mechanistic model of tumor growth formulated as a system of ordinary differential equations based on our prior work on modeling cancer response to various forms of drug treatment (<xref ref-type="bibr" rid="bib5">Brocato et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Brocato et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Dogra et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Goel et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Wang et al., 2016</xref>). The model accounts for two primary opposing processes: tumor cell growth and death caused by the CSSTRESAC peptide, while also allowing for competitive antagonism exhibited by 1,25-(OH)<sub>2</sub>D<sub>3</sub> in serum. To model tumor growth delay in gene therapy experiments, an extra death rate term was introduced that characterizes death due to GCV activated through <italic>HSVtk</italic>. Specifically, the tumor proliferation rate (<inline-formula><mml:math id="inf5"><mml:mi>G</mml:mi></mml:math></inline-formula>) is characterized through a logistic equation, the death rate (<inline-formula><mml:math id="inf6"><mml:mi>S</mml:mi></mml:math></inline-formula>) due to the peptide is modeled as a Michaelis-Menten kinetics process, and the death rate (<inline-formula><mml:math id="inf7"><mml:mi>N</mml:mi></mml:math></inline-formula>) due to GCV is modeled as a linear function of the concentration of GCV in plasma. Therefore, we obtain the following generic tumor growth model (equations 1 - 4), developed to capture changes in tumor volume (<inline-formula><mml:math id="inf8"><mml:mi>V</mml:mi></mml:math></inline-formula>) over time:<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>V</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>G</mml:mi><mml:mo>-</mml:mo><mml:mi>S</mml:mi><mml:mo>-</mml:mo><mml:mi>N</mml:mi><mml:mo>,</mml:mo></mml:math></disp-formula><disp-formula id="equ2"><mml:math id="m2"><mml:mi>G</mml:mi><mml:mo>=</mml:mo><mml:mi>σ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>V</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>⋅</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mi>V</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:math></disp-formula><disp-formula id="equ3"><mml:math id="m3"><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula><disp-formula id="equ4"><mml:math id="m4"><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mi>λ</mml:mi><mml:mo>⋅</mml:mo><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></disp-formula>where <inline-formula><mml:math id="inf9"><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the initial volume of the tumor, <inline-formula><mml:math id="inf10"><mml:mi>σ</mml:mi></mml:math></inline-formula> is the tumor growth rate constant, <inline-formula><mml:math id="inf11"><mml:mi>K</mml:mi></mml:math></inline-formula> is the carrying capacity of the host, <inline-formula><mml:math id="inf12"><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> is the plasma concentration of CSSTRESAC-AVVP-HSV<italic>tk</italic>, <inline-formula><mml:math id="inf13"><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> is the plasma concentration of GCV, <inline-formula><mml:math id="inf14"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the asymptotic death rate due to the peptide (indicative of potency), <inline-formula><mml:math id="inf15"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the CSSTRESAC-DBP-PDIA3 complex dissociation constant—which is implicitly a function of the concentration of 1,25-(OH)<sub>2</sub>D<sub>3</sub>—and <inline-formula><mml:math id="inf16"><mml:mi>λ</mml:mi></mml:math></inline-formula> is the proportionality constant between tumor volume and GCV concentration in plasma <inline-formula><mml:math id="inf17"><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>.</p><p>To estimate <inline-formula><mml:math id="inf18"><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> and <inline-formula><mml:math id="inf19"><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> for use in the tumor growth model, a one compartment pharmacokinetic (PK) model was employed. Given that the peptide was administered iv, we assumed a first-order renal clearance of the peptide, characterized by an excretion rate constant <inline-formula><mml:math id="inf20"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, such that:<disp-formula id="equ5"><label>(5)</label><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mspace width="2em"/><mml:mspace width="2em"/><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf21"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is the initial plasma concentration of soluble CSSTRESAC.</p><p>Further, given that GCV was administered ip, in addition to first-order renal excretion (rate constant <inline-formula><mml:math id="inf22"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>), a first-order absorption of GCV from the peritoneal cavity (rate constant <inline-formula><mml:math id="inf23"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>) into the bloodstream was also incorporated to model its plasma concentration <inline-formula><mml:math id="inf24"><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>. Hence, we obtain:<disp-formula id="equ6"><mml:math id="m6"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>d</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></disp-formula><disp-formula id="equ7"><mml:math id="m7"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></disp-formula><disp-formula id="equ8"><label>(8)</label><mml:math id="m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>I</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:mtd><mml:mtd><mml:mi>t</mml:mi><mml:mo>≤</mml:mo><mml:mn>5</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>μ</mml:mi><mml:mo>⋅</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo></mml:mtd><mml:mtd><mml:mi>t</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>5</mml:mn></mml:mtd></mml:mtr></mml:mtable><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf25"><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> is the concentration of GCV in the peritoneal cavity and <inline-formula><mml:math id="inf26"><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> is the initial concentration of GCV in the peritoneal cavity. A summary of the system of ordinary differential equations consistent with the dose regimen of the gene therapy experiment is shown below:<disp-formula id="equ9"><mml:math id="m9"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>G</mml:mi><mml:mo>-</mml:mo><mml:mi>N</mml:mi><mml:mo>-</mml:mo><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mi/><mml:mi/><mml:mi>V</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math></disp-formula><disp-formula id="equ10"><mml:math id="m10"><mml:mi>G</mml:mi><mml:mo>=</mml:mo><mml:mi>σ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>V</mml:mi><mml:mo>⋅</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo>,</mml:mo><mml:mi/><mml:mi/><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mi>λ</mml:mi><mml:mo>⋅</mml:mo><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mi/><mml:mi/><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:math></disp-formula><disp-formula id="equ11"><mml:math id="m11"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>d</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mi/><mml:mi/><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:math></disp-formula><disp-formula id="equ12"><mml:math id="m12"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:msubsup><mml:mo>⋅</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">P</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mi/><mml:mi/><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:math></disp-formula><disp-formula id="equ13"><mml:math id="m13"><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:munder><mml:mrow><mml:mi mathvariant="normal">lim</mml:mi></mml:mrow><mml:mrow><mml:mi>ε</mml:mi><mml:mo>→</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:munder></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>G</mml:mi><mml:mi>C</mml:mi><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mi>ε</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:msub><mml:mrow><mml:mo>+</mml:mo><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi/><mml:mi/><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>12,13</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mn>21</mml:mn></mml:math></disp-formula><disp-formula id="equ14"><mml:math id="m14"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>e</mml:mi><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mi/><mml:mi/><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:math></disp-formula><disp-formula id="equ15"><mml:math id="m15"><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:munder><mml:mrow><mml:mi mathvariant="normal">lim</mml:mi></mml:mrow><mml:mrow><mml:mi>ε</mml:mi><mml:mo>→</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:munder></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msubsup><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mi>ε</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi/><mml:mi/><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>5</mml:mn><mml:mi/><mml:mo>.</mml:mo></mml:math></disp-formula></p><p>In order to perform model parameterization, we began by sequentially fitting the model to the gene therapy data (<xref ref-type="fig" rid="fig3">Figure 3C</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) to estimate the unknown model parameters, which were later used to evaluate the pharmacodynamics of the soluble peptide given in treatment experiments (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). To estimate the tumor growth rate constant <inline-formula><mml:math id="inf27"><mml:mi>σ</mml:mi></mml:math></inline-formula>, we solved <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> for <inline-formula><mml:math id="inf28"><mml:mi>t</mml:mi></mml:math></inline-formula> in the range of 15– 21 days ignoring the terms <inline-formula><mml:math id="inf29"><mml:mi>N</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf30"><mml:mi>S</mml:mi></mml:math></inline-formula>, and used the data corresponding to GCV only (control) to drive a least squares optimization routine. Subsequently, we extrapolated tumor volume to time <inline-formula><mml:math id="inf31"><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> to obtain <inline-formula><mml:math id="inf32"><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, and then used this initial condition to solve <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> for <inline-formula><mml:math id="inf33"><mml:mi>t</mml:mi></mml:math></inline-formula> in the range of 0 to 21 days. At this step, the term <inline-formula><mml:math id="inf34"><mml:mi>N</mml:mi></mml:math></inline-formula> was retained but <inline-formula><mml:math id="inf35"><mml:mi>S</mml:mi></mml:math></inline-formula> was again set to zero, and the data corresponding to fd-AAVP-HSV<italic>tk</italic> + GCV group was then fit to estimate <inline-formula><mml:math id="inf36"><mml:mi>λ</mml:mi></mml:math></inline-formula>. Finally, the whole system including the term <inline-formula><mml:math id="inf37"><mml:mi>S</mml:mi></mml:math></inline-formula> was solved for 0–21 days and the data corresponding to CSSTRESAC-AAVP-HSV<italic>tk</italic> + GCV group was used to estimate the parameters <inline-formula><mml:math id="inf38"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf39"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="inf40"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>. Further, the system of equations 6 and 7 was fit to the literature-derived plasma concentration kinetics of GCV after ip administration in mice to extract the unknown parameters <inline-formula><mml:math id="inf41"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf42"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> for use in the tumor growth model. The computed parameters are shown in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p><p>In the above calculations, we assumed a mouse weight of 20 g, and a volume of 10 ml per kg for the peritoneal cavity. The administered ip dose of GCV was 80 mg/kg/day, that is, <inline-formula><mml:math id="inf43"><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.008</mml:mn></mml:math></inline-formula> mg/mm<sup>3</sup> and the iv administration of the peptide was <inline-formula><mml:math id="inf44"><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:math></inline-formula> mM. For all experiments, we used a carrying capacity <inline-formula><mml:math id="inf45"><mml:mi>K</mml:mi></mml:math></inline-formula> of 10<sup>4</sup> mm<sup>3</sup>. To comply with animal testing regulations, the tumor-bearing mice were killed much before the value 10<sup>4</sup> mm<sup>3</sup> was achieved; we however note that the allowable limit of tumor volumes during in vivo studies does not necessarily reflect the carrying capacity of the host. Hence, a literature-based value for <inline-formula><mml:math id="inf46"><mml:mi>K</mml:mi></mml:math></inline-formula> was used (<xref ref-type="bibr" rid="bib49">Wu et al., 2018</xref>). Of note, in the gene transfer experiments, the peptide is displayed on the AAVP particle, hence it has a different PK behavior (defined by <inline-formula><mml:math id="inf47"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>) than the soluble CSSTRESAC peptide. Therefore, the excretion rate constant of the soluble CSSTRESAC peptide was refit while modeling its pharmacodynamics and was denoted as <inline-formula><mml:math id="inf48"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>.</p><p>In terms of predictions from the model, we show the fit for in vivo experiments performed in experimental mouse models plus a simulated clinical trial for treatment of human breast cancer with soluble CSSTRESAC (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). The obtained value of <inline-formula><mml:math id="inf49"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>38.0</mml:mn><mml:mi/><mml:msup><mml:mrow><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, and the corresponding half-life of CSSTRESAC were computed as <inline-formula><mml:math id="inf50"><mml:msubsup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">ln</mml:mi></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mrow><mml:mo>/</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, which is ~26 min. Therefore, the half-life of the CSSTRESAC conforms to those of other targeting pharmacological data (<xref ref-type="bibr" rid="bib34">Pasqualini et al., 2015</xref>) and indicates that soluble CSSTRESAC is rapidly cleared through renal excretion. To evaluate the importance of a possible competitive binding between 1,25-(OH)<sub>2</sub>D<sub>3</sub> and soluble CSSTRESAC in the serum, the dissociation constant <inline-formula><mml:math id="inf51"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> was perturbed by ± 20% of the reference parameter value. As such, an increase in <inline-formula><mml:math id="inf52"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> would reflect the competitive binding of the antagonist 1,25-(OH)<sub>2</sub>D<sub>3</sub>, where the dissociation of CSSTRESAC from PDIA3 on the cell surface increases and the antitumor effects of CSSTRESAC decreases. Similarly, a reduced <inline-formula><mml:math id="inf53"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> would reflect a stronger binding between CCSTRESAC and PDIA3 with the consequent inhibition of tumor growth (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><p>We also considered a hypothetical experiment in human patients where a constant rate of iv infusion of the soluble CSSTRESAC peptide was compared to the efficacy of a unit i.v. bolus. In this scenario, the kinetics of the soluble CSSTRESAC peptide is dictated by equation 8. The infusion constant µ denotes the asymptotic concentration of the peptide and <inline-formula><mml:math id="inf54"><mml:mi>I</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> is the infusion rate. Our mathematical model predicted that infusion of CCSTRESAC (µ = 0.75) would resulted in greater reduction in tumor volume compared to bolus (<xref ref-type="fig" rid="fig4">Figure 4A</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Thus, this in silico experiment clearly illustrates the use of a mathematical model in predicting potential therapeutic effects and limitations of soluble CSSTRESAC. Similarly, our mathematical model when fit to the experimental data showed satisfactory agreement as indicated by the Pearson correlation coefficient <inline-formula><mml:math id="inf55"><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.998</mml:mn></mml:math></inline-formula> (p = 0.001) (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). The model parameter estimates are listed (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p></sec><sec id="s4-13"><title>PDIA3 gene expression in human single cells from TNBC patients</title><p>In order to evaluate the expression levels of <italic>PDIA3</italic> mRNA in human breast cancer samples, we obtained the clinical and scRNA-seq data from a publicly available single cell database from TNBC patients (BC07 - BC11) as originally reported (<xref ref-type="bibr" rid="bib9">Chung et al., 2017</xref>). The scRNA-seq datasets were reported as TPM and were assessed through the GEO repository (accession number GSE75688). Gene expression levels of 35 pre-defined myeloid cells were retrieved and distributed into three groups according to <italic>PDIA3</italic> expression levels (set as high, medium, or low). A heat-map was generated to show potential associations between <italic>PDIA3</italic> and gene pathways characteristic of macrophages.</p></sec><sec id="s4-14"><title>Statistical analysis</title><p>Comparisons among the groups were assessed by One-way ANOVA with SigmaStat (SPSS Inc) and GraphPad Prism (GraphPad Software Inc). Statistical significance was set at a p-value of &lt;0.05 unless otherwise specified. Normally distributed data are shown as bar graphs with means ± standard deviation (SD) or standard error of the mean (SEM) as indicated, whereas not normally distributed data are shown in box-and-whiskers plots: the boxes define the 25th and 75th percentiles, a line denotes the median and error bars define the 10th and 90th percentiles.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the US DOD IMPACT grant W81XWH-09-1-0224 and by serial awards from the Gillson-Longenbaugh Foundation and the Susan G Komen Breast Cancer Foundation (to WA and RP). The RCSB Protein Data Bank is supported by grants to SKB from the National Science Foundation (DBI-1832184), the NIH (R01GM133198), and the US DOE (DE-SC0019749). This work has also been supported by the National Science Foundation Grant DMS-1930583 (ZW, VC), NIH Grants 1U01CA196403 (ZW, VC), 1U01CA213759 (ZW, VC), 1R01CA226537 (ZW, VC, WA, RP), 1R01CA222007 (ZW, VC), and U54CA210181 (ZW, VC). MC was partially funded by FAPESP (2012/24105-3, 2020/13562–0). We thank Dr. Helen Pickersgill (Life Science Editors) for professional editing and Dr. Webster K Cavenee, Dr. Sylvia Christakos, and Dr. E Helene Sage for critical reading of the manuscript. JGG, WA, and RP are founders and equity stockholders of PhageNova Bio, which has licensed reagents disclosed in this manuscript. AH, WHPD, BP, WA and RP are entitled to royalty payments from this licensing agreement. RP is the Chief Scientific Officer and a paid consultant for PhageNova Bio. WA and RP are partially supported by a Sponsored Research Agreement from PhageNova Bio. AH, JGG, WA, and RP are inventors on issued and pending patent applications related to technology disclosed in this manuscript and will be entitled to royalties if licensing or commercialization occurs. WA and RP are also founders and equity holders of MBrace Therapeutics. RP serves as a Board Member of MBrace Therapeutics. These arrangements are managed and monitored in accordance with the established institutional conflict of interest policies of Rutgers, the State University of New Jersey. MC is a consultant for CytoDyn, Sermonix Pharmaceuticals, G1 Therapeutics, Foundation Medicine, Dompé, ArcherDX and Menarini. MC also receives honoraria/travel grants from Pfizer, Lilly, Novartis, Sermonix Pharmaceuticals, Foundation Medicine and Menarini. Other authors declare that they have no competing interests.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is a founder and equity stockholder of PhageNova Bio, which has licensed reagents disclosed in this manuscript. JGG is also an inventor on issued and pending patent applications related to technology disclosed in this manuscript and will be entitled to royalties if licensing or commercialization occurs</p></fn><fn fn-type="COI-statement" id="conf3"><p>is a founder and equity stockholder of PhageNova Bio, which has licensed reagents disclosed in this manuscript. WA is entitled to royalty payments from this licensing agreement. WA is partially supported by a Sponsored Research Agreement from PhageNova Bio. WA is an inventor on issued and pending patent applications related to technology disclosed in this manuscript and will be entitled to royalties if licensing or commercialization occurs. WA is also a founder and equity holder of MBrace Therapeutics.</p></fn><fn fn-type="COI-statement" id="conf4"><p>is a founder and equity stockholder of PhageNova Bio, which has licensed reagents disclosed in this manuscript. RP is entitled to royalty payments from this licensing agreement. RP is the Chief Scientific Officer and a paid consultant for PhageNova Bio. RP is partially supported by a Sponsored Research Agreement from PhageNova Bio. RP is an inventor on issued and pending patent applications related to technology disclosed in this manuscript and will be entitled to royalties if licensing or commercialization occurs. RP is also a founder and equity holder of MBrace Therapeutics. RP serves as a Board Member of MBrace Therapeutics.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con22"><p>Conceptualization, Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con23"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con24"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con25"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con26"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con27"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con28"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con29"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Validation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con30"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: Eight-week-old female nude (nu/nu) mice and immunocompetent BALB/c mice were housed in the animal facilities of the University of Texas M.D. Anderson Cancer Center # 11-99-09935 and Rutgers University New Jersey Medical School (PROTO201800055), all in the USA. All animal procedures were reviewed and approved by the corresponding Institutional Animal Care and Use Committee (IACUC)-equivalent at each institution.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>MS/MS analysis of CSSTRESAC-binding proteins.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65145-supp1-v1.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Computer parameters of the mathematical model.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-65145-supp2-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-65145-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided in Materials and methods and Supplementary files.</p><p>The following previously published dataset was used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>W</given-names></name><name><surname>Eum</surname><given-names>HH</given-names></name><name><surname>Lee</surname><given-names>HO</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>HB</given-names></name><name><surname>Kim</surname><given-names>KT</given-names></name><name><surname>Ryu</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Park</surname><given-names>YH</given-names></name><name><surname>Kan</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Park</surname><given-names>WY</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75688">GSE75688</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>LM</given-names></name><name><surname>Ethier</surname> <given-names>SP</given-names></name><name><surname>Ullrich</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Enhanced in vitro proliferation and in vivo tumorigenic potential of mammary epithelium from BALB/c mice exposed in vivo to gamma-radiation and/or 7,12-dimethylbenz[a]anthracene</article-title><source>Cancer Research</source><volume>47</volume><fpage>4425</fpage><lpage>4431</lpage><pub-id pub-id-type="pmid">3111686</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arap</surname> <given-names>W</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Ruoslahti</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model</article-title><source>Science</source><volume>279</volume><fpage>377</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1126/science.279.5349.377</pub-id><pub-id pub-id-type="pmid">9430587</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname> <given-names>T</given-names></name><name><surname>Efird</surname> <given-names>JT</given-names></name><name><surname>Prasad</surname> <given-names>S</given-names></name><name><surname>James</surname> <given-names>SE</given-names></name><name><surname>Walker</surname> <given-names>PR</given-names></name><name><surname>Zagar</surname> <given-names>TM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inflammatory TNBC breast Cancer: demography and clinical outcome in a large cohort of patients with TNBC</article-title><source>Clinical Breast Cancer</source><volume>16</volume><fpage>212</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.clbc.2016.02.004</pub-id><pub-id pub-id-type="pmid">26988771</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname> <given-names>SK</given-names></name><name><surname>Mantovani</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm</article-title><source>Nature Immunology</source><volume>11</volume><fpage>889</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1038/ni.1937</pub-id><pub-id pub-id-type="pmid">20856220</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brocato</surname> <given-names>TA</given-names></name><name><surname>Coker</surname> <given-names>EN</given-names></name><name><surname>Durfee</surname> <given-names>PN</given-names></name><name><surname>Lin</surname> <given-names>YS</given-names></name><name><surname>Townson</surname> <given-names>J</given-names></name><name><surname>Wyckoff</surname> <given-names>EF</given-names></name><name><surname>Cristini</surname> <given-names>V</given-names></name><name><surname>Brinker</surname> <given-names>CJ</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Understanding the connection between nanoparticle uptake and Cancer treatment efficacy using mathematical modeling</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>7538</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-25878-8</pub-id><pub-id pub-id-type="pmid">29795392</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brocato</surname> <given-names>TA</given-names></name><name><surname>Brown-Glaberman</surname> <given-names>U</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Selwyn</surname> <given-names>RG</given-names></name><name><surname>Wilson</surname> <given-names>CM</given-names></name><name><surname>Wyckoff</surname> <given-names>EF</given-names></name><name><surname>Lomo</surname> <given-names>LC</given-names></name><name><surname>Saline</surname> <given-names>JL</given-names></name><name><surname>Hooda-Nehra</surname> <given-names>A</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name><name><surname>Brinker</surname> <given-names>CJ</given-names></name><name><surname>Cristini</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Predicting breast Cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>e126518</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.126518</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cailleau</surname> <given-names>R</given-names></name><name><surname>Young</surname> <given-names>R</given-names></name><name><surname>Olivé</surname> <given-names>M</given-names></name><name><surname>Reeves</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="1974">1974</year><article-title>Breast tumor cell lines from pleural effusions</article-title><source>JNCI: Journal of the National Cancer Institute</source><volume>53</volume><fpage>661</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1093/jnci/53.3.661</pub-id><pub-id pub-id-type="pmid">4412247</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christakos</surname> <given-names>S</given-names></name><name><surname>Dhawan</surname> <given-names>P</given-names></name><name><surname>Verstuyf</surname> <given-names>A</given-names></name><name><surname>Verlinden</surname> <given-names>L</given-names></name><name><surname>Carmeliet</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects</article-title><source>Physiological Reviews</source><volume>96</volume><fpage>365</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1152/physrev.00014.2015</pub-id><pub-id pub-id-type="pmid">26681795</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname> <given-names>W</given-names></name><name><surname>Eum</surname> <given-names>HH</given-names></name><name><surname>Lee</surname> <given-names>HO</given-names></name><name><surname>Lee</surname> <given-names>KM</given-names></name><name><surname>Lee</surname> <given-names>HB</given-names></name><name><surname>Kim</surname> <given-names>KT</given-names></name><name><surname>Ryu</surname> <given-names>HS</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>JE</given-names></name><name><surname>Park</surname> <given-names>YH</given-names></name><name><surname>Kan</surname> <given-names>Z</given-names></name><name><surname>Han</surname> <given-names>W</given-names></name><name><surname>Park</surname> <given-names>WY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast Cancer</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15081</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15081</pub-id><pub-id pub-id-type="pmid">28474673</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlin</surname> <given-names>SS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epidemiology of breast Cancer in women</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1152</volume><fpage>9</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-20301-6_2</pub-id><pub-id pub-id-type="pmid">31456177</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeNardo</surname> <given-names>DG</given-names></name><name><surname>Ruffell</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macrophages as regulators of tumour immunity and immunotherapy</article-title><source>Nature Reviews Immunology</source><volume>19</volume><fpage>369</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0127-6</pub-id><pub-id pub-id-type="pmid">30718830</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dent</surname> <given-names>R</given-names></name><name><surname>Trudeau</surname> <given-names>M</given-names></name><name><surname>Pritchard</surname> <given-names>KI</given-names></name><name><surname>Hanna</surname> <given-names>WM</given-names></name><name><surname>Kahn</surname> <given-names>HK</given-names></name><name><surname>Sawka</surname> <given-names>CA</given-names></name><name><surname>Lickley</surname> <given-names>LA</given-names></name><name><surname>Rawlinson</surname> <given-names>E</given-names></name><name><surname>Sun</surname> <given-names>P</given-names></name><name><surname>Narod</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Triple-negative breast Cancer: clinical features and patterns of recurrence</article-title><source>Clinical Cancer Research</source><volume>13</volume><fpage>4429</fpage><lpage>4434</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-3045</pub-id><pub-id pub-id-type="pmid">17671126</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietze</surname> <given-names>EC</given-names></name><name><surname>Sistrunk</surname> <given-names>C</given-names></name><name><surname>Miranda-Carboni</surname> <given-names>G</given-names></name><name><surname>O'Regan</surname> <given-names>R</given-names></name><name><surname>Seewaldt</surname> <given-names>VL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Triple-negative breast Cancer in African-American women: disparities versus biology</article-title><source>Nature Reviews Cancer</source><volume>15</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/nrc3896</pub-id><pub-id pub-id-type="pmid">25673085</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobroff</surname> <given-names>AS</given-names></name><name><surname>D'Angelo</surname> <given-names>S</given-names></name><name><surname>Eckhardt</surname> <given-names>BL</given-names></name><name><surname>Ferrara</surname> <given-names>F</given-names></name><name><surname>Staquicini</surname> <given-names>DI</given-names></name><name><surname>Cardó-Vila</surname> <given-names>M</given-names></name><name><surname>Staquicini</surname> <given-names>FI</given-names></name><name><surname>Nunes</surname> <given-names>DN</given-names></name><name><surname>Kim</surname> <given-names>K</given-names></name><name><surname>Driessen</surname> <given-names>WHP</given-names></name><name><surname>Hajitou</surname> <given-names>A</given-names></name><name><surname>Lomo</surname> <given-names>LC</given-names></name><name><surname>Barry</surname> <given-names>M</given-names></name><name><surname>Krishnamurthy</surname> <given-names>S</given-names></name><name><surname>Sahin</surname> <given-names>A</given-names></name><name><surname>Woodward</surname> <given-names>WA</given-names></name><name><surname>Prossnitz</surname> <given-names>ER</given-names></name><name><surname>Anderson</surname> <given-names>RL</given-names></name><name><surname>Dias-Neto</surname> <given-names>E</given-names></name><name><surname>Brown-Glaberman</surname> <given-names>UA</given-names></name><name><surname>Royce</surname> <given-names>ME</given-names></name><name><surname>Ueno</surname> <given-names>NT</given-names></name><name><surname>Cristofanilli</surname> <given-names>M</given-names></name><name><surname>Hortobagyi</surname> <given-names>GN</given-names></name><name><surname>Marchiò</surname> <given-names>S</given-names></name><name><surname>Gelovani</surname> <given-names>JG</given-names></name><name><surname>Sidman</surname> <given-names>RL</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Towards a transcriptome-based theranostic platform for unfavorable breast Cancer phenotypes</article-title><source>PNAS</source><volume>113</volume><fpage>12780</fpage><lpage>12785</lpage><pub-id pub-id-type="doi">10.1073/pnas.1615288113</pub-id><pub-id pub-id-type="pmid">27791177</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogra</surname> <given-names>P</given-names></name><name><surname>Adolphi</surname> <given-names>NL</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Lin</surname> <given-names>YS</given-names></name><name><surname>Butler</surname> <given-names>KS</given-names></name><name><surname>Durfee</surname> <given-names>PN</given-names></name><name><surname>Croissant</surname> <given-names>JG</given-names></name><name><surname>Noureddine</surname> <given-names>A</given-names></name><name><surname>Coker</surname> <given-names>EN</given-names></name><name><surname>Bearer</surname> <given-names>EL</given-names></name><name><surname>Cristini</surname> <given-names>V</given-names></name><name><surname>Brinker</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4551</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06730-z</pub-id><pub-id pub-id-type="pmid">30382084</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname> <given-names>F</given-names></name><name><surname>Staquicini</surname> <given-names>DI</given-names></name><name><surname>Driessen</surname> <given-names>WHP</given-names></name><name><surname>D'Angelo</surname> <given-names>S</given-names></name><name><surname>Dobroff</surname> <given-names>AS</given-names></name><name><surname>Barry</surname> <given-names>M</given-names></name><name><surname>Lomo</surname> <given-names>LC</given-names></name><name><surname>Staquicini</surname> <given-names>FI</given-names></name><name><surname>Cardó-Vila</surname> <given-names>M</given-names></name><name><surname>Soghomonyan</surname> <given-names>S</given-names></name><name><surname>Alauddin</surname> <given-names>MM</given-names></name><name><surname>Flores</surname> <given-names>LG</given-names></name><name><surname>Arap</surname> <given-names>MA</given-names></name><name><surname>Lauer</surname> <given-names>RC</given-names></name><name><surname>Mathew</surname> <given-names>P</given-names></name><name><surname>Efstathiou</surname> <given-names>E</given-names></name><name><surname>Aparicio</surname> <given-names>AM</given-names></name><name><surname>Troncoso</surname> <given-names>P</given-names></name><name><surname>Navone</surname> <given-names>NM</given-names></name><name><surname>Logothetis</surname> <given-names>CJ</given-names></name><name><surname>Marchiò</surname> <given-names>S</given-names></name><name><surname>Gelovani</surname> <given-names>JG</given-names></name><name><surname>Sidman</surname> <given-names>RL</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer</article-title><source>PNAS</source><volume>113</volume><fpage>12786</fpage><lpage>12791</lpage><pub-id pub-id-type="doi">10.1073/pnas.1615400113</pub-id><pub-id pub-id-type="pmid">27791181</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido-Castro</surname> <given-names>AC</given-names></name><name><surname>Lin</surname> <given-names>NU</given-names></name><name><surname>Polyak</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Insights into molecular classifications of Triple-Negative breast Cancer: improving patient selection for treatment</article-title><source>Cancer Discovery</source><volume>9</volume><fpage>176</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-1177</pub-id><pub-id pub-id-type="pmid">30679171</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname> <given-names>RJ</given-names></name><name><surname>Cardó-Vila</surname> <given-names>M</given-names></name><name><surname>Lahdenranta</surname> <given-names>J</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Biopanning and rapid analysis of selective interactive ligands</article-title><source>Nature Medicine</source><volume>7</volume><fpage>1249</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1038/nm1101-1249</pub-id><pub-id pub-id-type="pmid">11689892</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname> <given-names>S</given-names></name><name><surname>Ferreira</surname> <given-names>CA</given-names></name><name><surname>Dogra</surname> <given-names>P</given-names></name><name><surname>Yu</surname> <given-names>B</given-names></name><name><surname>Kutyreff</surname> <given-names>CJ</given-names></name><name><surname>Siamof</surname> <given-names>CM</given-names></name><name><surname>Engle</surname> <given-names>JW</given-names></name><name><surname>Barnhart</surname> <given-names>TE</given-names></name><name><surname>Cristini</surname> <given-names>V</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Cai</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Size-Optimized ultrasmall porous silica nanoparticles depict Vasculature-Based differential targeting in triple negative breast Cancer</article-title><source>Small</source><volume>15</volume><elocation-id>1903747</elocation-id><pub-id pub-id-type="doi">10.1002/smll.201903747</pub-id><pub-id pub-id-type="pmid">31565854</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname> <given-names>CT</given-names></name><name><surname>Cardiff</surname> <given-names>RD</given-names></name><name><surname>Muller</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease</article-title><source>Molecular and Cellular Biology</source><volume>12</volume><fpage>954</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1128/mcb.12.3.954</pub-id><pub-id pub-id-type="pmid">1312220</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajitou</surname> <given-names>A</given-names></name><name><surname>Baramova</surname> <given-names>EN</given-names></name><name><surname>Bajou</surname> <given-names>K</given-names></name><name><surname>Noë</surname> <given-names>V</given-names></name><name><surname>Bruyneel</surname> <given-names>E</given-names></name><name><surname>Mareel</surname> <given-names>M</given-names></name><name><surname>Collette</surname> <given-names>J</given-names></name><name><surname>Foidart</surname> <given-names>JM</given-names></name><name><surname>Calberg-Bacq</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells</article-title><source>Oncogene</source><volume>17</volume><fpage>2059</fpage><lpage>2071</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202126</pub-id><pub-id pub-id-type="pmid">9798677</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajitou</surname> <given-names>A</given-names></name><name><surname>Trepel</surname> <given-names>M</given-names></name><name><surname>Lilley</surname> <given-names>CE</given-names></name><name><surname>Soghomonyan</surname> <given-names>S</given-names></name><name><surname>Alauddin</surname> <given-names>MM</given-names></name><name><surname>Marini</surname> <given-names>FC</given-names></name><name><surname>Restel</surname> <given-names>BH</given-names></name><name><surname>Ozawa</surname> <given-names>MG</given-names></name><name><surname>Moya</surname> <given-names>CA</given-names></name><name><surname>Rangel</surname> <given-names>R</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Zaoui</surname> <given-names>K</given-names></name><name><surname>Schmidt</surname> <given-names>M</given-names></name><name><surname>von Kalle</surname> <given-names>C</given-names></name><name><surname>Weitzman</surname> <given-names>MD</given-names></name><name><surname>Gelovani</surname> <given-names>JG</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A hybrid vector for ligand-directed tumor targeting and molecular imaging</article-title><source>Cell</source><volume>125</volume><fpage>385</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.02.042</pub-id><pub-id pub-id-type="pmid">16630824</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>MA</given-names></name><name><surname>Jain</surname> <given-names>VK</given-names></name><name><surname>Rizwanullah</surname> <given-names>M</given-names></name><name><surname>Ahmad</surname> <given-names>J</given-names></name><name><surname>Jain</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PI3K/AKT/mTOR pathway inhibitors in triple-negative breast Cancer: a review on drug discovery and future challenges</article-title><source>Drug Discovery Today</source><volume>24</volume><fpage>2181</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2019.09.001</pub-id><pub-id pub-id-type="pmid">31520748</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanal</surname> <given-names>RC</given-names></name><name><surname>Nemere</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The ERp57/GRp58/1,25D3-MARRS receptor: multiple functional roles in diverse cell systems</article-title><source>Current Medicinal Chemistry</source><volume>14</volume><fpage>1087</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.2174/092986707780362871</pub-id><pub-id pub-id-type="pmid">17456022</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>B</given-names></name><name><surname>Woodward</surname> <given-names>WA</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Reuben</surname> <given-names>JM</given-names></name><name><surname>Ueno</surname> <given-names>NT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inflammatory breast Cancer biology: the tumour microenvironment is key</article-title><source>Nature Reviews Cancer</source><volume>18</volume><fpage>485</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0010-y</pub-id><pub-id pub-id-type="pmid">29703913</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyons</surname> <given-names>TG</given-names></name><name><surname>Traina</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Emerging novel therapeutics in Triple-Negative breast Cancer</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1152</volume><fpage>377</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-20301-6_20</pub-id><pub-id pub-id-type="pmid">31456195</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maglione</surname> <given-names>JE</given-names></name><name><surname>Moghanaki</surname> <given-names>D</given-names></name><name><surname>Young</surname> <given-names>LJ</given-names></name><name><surname>Manner</surname> <given-names>CK</given-names></name><name><surname>Ellies</surname> <given-names>LG</given-names></name><name><surname>Joseph</surname> <given-names>SO</given-names></name><name><surname>Nicholson</surname> <given-names>B</given-names></name><name><surname>Cardiff</surname> <given-names>RD</given-names></name><name><surname>MacLeod</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Transgenic polyoma middle-T mice model premalignant mammary disease</article-title><source>Cancer Research</source><volume>61</volume><fpage>8298</fpage><lpage>8305</lpage><pub-id pub-id-type="pmid">11719463</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchiò</surname> <given-names>S</given-names></name><name><surname>Lahdenranta</surname> <given-names>J</given-names></name><name><surname>Schlingemann</surname> <given-names>RO</given-names></name><name><surname>Valdembri</surname> <given-names>D</given-names></name><name><surname>Wesseling</surname> <given-names>P</given-names></name><name><surname>Arap</surname> <given-names>MA</given-names></name><name><surname>Hajitou</surname> <given-names>A</given-names></name><name><surname>Ozawa</surname> <given-names>MG</given-names></name><name><surname>Trepel</surname> <given-names>M</given-names></name><name><surname>Giordano</surname> <given-names>RJ</given-names></name><name><surname>Nanus</surname> <given-names>DM</given-names></name><name><surname>Dijkman</surname> <given-names>HB</given-names></name><name><surname>Oosterwijk</surname> <given-names>E</given-names></name><name><surname>Sidman</surname> <given-names>RL</given-names></name><name><surname>Cooper</surname> <given-names>MD</given-names></name><name><surname>Bussolino</surname> <given-names>F</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Aminopeptidase A is a functional target in angiogenic blood vessels</article-title><source>Cancer Cell</source><volume>5</volume><fpage>151</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(04)00025-X</pub-id><pub-id pub-id-type="pmid">14998491</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marra</surname> <given-names>A</given-names></name><name><surname>Viale</surname> <given-names>G</given-names></name><name><surname>Curigliano</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Recent advances in triple negative breast Cancer: the immunotherapy era</article-title><source>BMC Medicine</source><volume>17</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s12916-019-1326-5</pub-id><pub-id pub-id-type="pmid">31068190</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michelfelder</surname> <given-names>S</given-names></name><name><surname>Kohlschütter</surname> <given-names>J</given-names></name><name><surname>Skorupa</surname> <given-names>A</given-names></name><name><surname>Pfennings</surname> <given-names>S</given-names></name><name><surname>Müller</surname> <given-names>O</given-names></name><name><surname>Kleinschmidt</surname> <given-names>JA</given-names></name><name><surname>Trepel</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e5122</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0005122</pub-id><pub-id pub-id-type="pmid">19357785</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname> <given-names>LA</given-names></name><name><surname>Kaljee</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Health disparities and Triple-Negative breast Cancer in african american women: a review</article-title><source>JAMA Surgery</source><volume>152</volume><fpage>485</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1001/jamasurg.2017.0005</pub-id><pub-id pub-id-type="pmid">28355428</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otterbein</surname> <given-names>LR</given-names></name><name><surname>Cosio</surname> <given-names>C</given-names></name><name><surname>Graceffa</surname> <given-names>P</given-names></name><name><surname>Dominguez</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Crystal structures of the vitamin D-binding protein and its complex with actin: structural basis of the actin-scavenger system</article-title><source>PNAS</source><volume>99</volume><fpage>8003</fpage><lpage>8008</lpage><pub-id pub-id-type="doi">10.1073/pnas.122126299</pub-id><pub-id pub-id-type="pmid">12048248</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozawa</surname> <given-names>MG</given-names></name><name><surname>Zurita</surname> <given-names>AJ</given-names></name><name><surname>Dias-Neto</surname> <given-names>E</given-names></name><name><surname>Nunes</surname> <given-names>DN</given-names></name><name><surname>Sidman</surname> <given-names>RL</given-names></name><name><surname>Gelovani</surname> <given-names>JG</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodelivery systems</article-title><source>Trends in Cardiovascular Medicine</source><volume>18</volume><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2008.03.001</pub-id><pub-id pub-id-type="pmid">18555185</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Millikan</surname> <given-names>RE</given-names></name><name><surname>Christianson</surname> <given-names>DR</given-names></name><name><surname>Cardó-Vila</surname> <given-names>M</given-names></name><name><surname>Driessen</surname> <given-names>WH</given-names></name><name><surname>Giordano</surname> <given-names>RJ</given-names></name><name><surname>Hajitou</surname> <given-names>A</given-names></name><name><surname>Hoang</surname> <given-names>AG</given-names></name><name><surname>Wen</surname> <given-names>S</given-names></name><name><surname>Barnhart</surname> <given-names>KF</given-names></name><name><surname>Baze</surname> <given-names>WB</given-names></name><name><surname>Marcott</surname> <given-names>VD</given-names></name><name><surname>Hawke</surname> <given-names>DH</given-names></name><name><surname>Do</surname> <given-names>KA</given-names></name><name><surname>Navone</surname> <given-names>NM</given-names></name><name><surname>Efstathiou</surname> <given-names>E</given-names></name><name><surname>Troncoso</surname> <given-names>P</given-names></name><name><surname>Lobb</surname> <given-names>RR</given-names></name><name><surname>Logothetis</surname> <given-names>CJ</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Targeting the interleukin-11 receptor α in metastatic prostate Cancer: a first-in-man study</article-title><source>Cancer</source><volume>121</volume><fpage>2411</fpage><lpage>2421</lpage><pub-id pub-id-type="doi">10.1002/cncr.29344</pub-id><pub-id pub-id-type="pmid">25832466</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Ruoslahti</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Organ targeting in vivo using phage display peptide libraries</article-title><source>Nature</source><volume>380</volume><fpage>364</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1038/380364a0</pub-id><pub-id pub-id-type="pmid">8598934</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Sørlie</surname> <given-names>T</given-names></name><name><surname>Eisen</surname> <given-names>MB</given-names></name><name><surname>van de Rijn</surname> <given-names>M</given-names></name><name><surname>Jeffrey</surname> <given-names>SS</given-names></name><name><surname>Rees</surname> <given-names>CA</given-names></name><name><surname>Pollack</surname> <given-names>JR</given-names></name><name><surname>Ross</surname> <given-names>DT</given-names></name><name><surname>Johnsen</surname> <given-names>H</given-names></name><name><surname>Akslen</surname> <given-names>LA</given-names></name><name><surname>Fluge</surname> <given-names>O</given-names></name><name><surname>Pergamenschikov</surname> <given-names>A</given-names></name><name><surname>Williams</surname> <given-names>C</given-names></name><name><surname>Zhu</surname> <given-names>SX</given-names></name><name><surname>Lønning</surname> <given-names>PE</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Brown</surname> <given-names>PO</given-names></name><name><surname>Botstein</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Molecular portraits of human breast tumours</article-title><source>Nature</source><volume>406</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1038/35021093</pub-id><pub-id pub-id-type="pmid">10963602</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname> <given-names>EF</given-names></name><name><surname>Goddard</surname> <given-names>TD</given-names></name><name><surname>Huang</surname> <given-names>CC</given-names></name><name><surname>Couch</surname> <given-names>GS</given-names></name><name><surname>Greenblatt</surname> <given-names>DM</given-names></name><name><surname>Meng</surname> <given-names>EC</given-names></name><name><surname>Ferrin</surname> <given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raveh</surname> <given-names>B</given-names></name><name><surname>London</surname> <given-names>N</given-names></name><name><surname>Zimmerman</surname> <given-names>L</given-names></name><name><surname>Schueler-Furman</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Rosetta FlexPepDock ab-initio: simultaneous folding, docking and refinement of peptides onto their receptors</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e18934</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018934</pub-id><pub-id pub-id-type="pmid">21572516</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schettini</surname> <given-names>F</given-names></name><name><surname>Giuliano</surname> <given-names>M</given-names></name><name><surname>De Placido</surname> <given-names>S</given-names></name><name><surname>Arpino</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Nab-paclitaxel for the treatment of triple-negative breast Cancer: rationale, clinical data and future perspectives</article-title><source>Cancer Treatment Reviews</source><volume>50</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2016.09.004</pub-id><pub-id pub-id-type="pmid">27665540</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Maupetit</surname> <given-names>J</given-names></name><name><surname>Derreumaux</surname> <given-names>P</given-names></name><name><surname>Tufféry</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved PEP-FOLD approach for peptide and miniprotein structure prediction</article-title><source>Journal of Chemical Theory and Computation</source><volume>10</volume><fpage>4745</fpage><lpage>4758</lpage><pub-id pub-id-type="doi">10.1021/ct500592m</pub-id><pub-id pub-id-type="pmid">26588162</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>TL</given-names></name><name><surname>Yuan</surname> <given-names>Z</given-names></name><name><surname>Cardó-Vila</surname> <given-names>M</given-names></name><name><surname>Sanchez Claros</surname> <given-names>C</given-names></name><name><surname>Adem</surname> <given-names>A</given-names></name><name><surname>Cui</surname> <given-names>MH</given-names></name><name><surname>Branch</surname> <given-names>CA</given-names></name><name><surname>Gelovani</surname> <given-names>JG</given-names></name><name><surname>Libutti</surname> <given-names>SK</given-names></name><name><surname>Sidman</surname> <given-names>RL</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas</article-title><source>PNAS</source><volume>113</volume><fpage>2466</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.1073/pnas.1525709113</pub-id><pub-id pub-id-type="pmid">26884209</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staquicini</surname> <given-names>FI</given-names></name><name><surname>Dias-Neto</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Snyder</surname> <given-names>EY</given-names></name><name><surname>Sidman</surname> <given-names>RL</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Discovery of a functional protein complex of netrin-4, laminin gamma1 chain, and integrin alpha6beta1 in mouse neural stem cells</article-title><source>PNAS</source><volume>106</volume><fpage>2903</fpage><lpage>2908</lpage><pub-id pub-id-type="doi">10.1073/pnas.0813286106</pub-id><pub-id pub-id-type="pmid">19193855</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staquicini</surname> <given-names>FI</given-names></name><name><surname>Ozawa</surname> <given-names>MG</given-names></name><name><surname>Moya</surname> <given-names>CA</given-names></name><name><surname>Driessen</surname> <given-names>WH</given-names></name><name><surname>Barbu</surname> <given-names>EM</given-names></name><name><surname>Nishimori</surname> <given-names>H</given-names></name><name><surname>Soghomonyan</surname> <given-names>S</given-names></name><name><surname>Flores</surname> <given-names>LG</given-names></name><name><surname>Liang</surname> <given-names>X</given-names></name><name><surname>Paolillo</surname> <given-names>V</given-names></name><name><surname>Alauddin</surname> <given-names>MM</given-names></name><name><surname>Basilion</surname> <given-names>JP</given-names></name><name><surname>Furnari</surname> <given-names>FB</given-names></name><name><surname>Bogler</surname> <given-names>O</given-names></name><name><surname>Lang</surname> <given-names>FF</given-names></name><name><surname>Aldape</surname> <given-names>KD</given-names></name><name><surname>Fuller</surname> <given-names>GN</given-names></name><name><surname>Höök</surname> <given-names>M</given-names></name><name><surname>Gelovani</surname> <given-names>JG</given-names></name><name><surname>Sidman</surname> <given-names>RL</given-names></name><name><surname>Cavenee</surname> <given-names>WK</given-names></name><name><surname>Pasqualini</surname> <given-names>R</given-names></name><name><surname>Arap</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma</article-title><source>Journal of Clinical Investigation</source><volume>121</volume><fpage>161</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1172/JCI44798</pub-id><pub-id pub-id-type="pmid">21183793</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>AHY</given-names></name><name><surname>Tu</surname> <given-names>W</given-names></name><name><surname>McCuaig</surname> <given-names>R</given-names></name><name><surname>Hardy</surname> <given-names>K</given-names></name><name><surname>Donovan</surname> <given-names>T</given-names></name><name><surname>Tsimbalyuk</surname> <given-names>S</given-names></name><name><surname>Forwood</surname> <given-names>JK</given-names></name><name><surname>Rao</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lysine-specific histone demethylase 1A regulates macrophage polarization and checkpoint molecules in the tumor microenvironment of triple negative breast Cancer</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1351</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01351</pub-id><pub-id pub-id-type="pmid">31249575</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tjuvajev</surname> <given-names>JG</given-names></name><name><surname>Avril</surname> <given-names>N</given-names></name><name><surname>Oku</surname> <given-names>T</given-names></name><name><surname>Sasajima</surname> <given-names>T</given-names></name><name><surname>Miyagawa</surname> <given-names>T</given-names></name><name><surname>Joshi</surname> <given-names>R</given-names></name><name><surname>Safer</surname> <given-names>M</given-names></name><name><surname>Beattie</surname> <given-names>B</given-names></name><name><surname>DiResta</surname> <given-names>G</given-names></name><name><surname>Daghighian</surname> <given-names>F</given-names></name><name><surname>Augensen</surname> <given-names>F</given-names></name><name><surname>Koutcher</surname> <given-names>J</given-names></name><name><surname>Zweit</surname> <given-names>J</given-names></name><name><surname>Humm</surname> <given-names>J</given-names></name><name><surname>Larson</surname> <given-names>SM</given-names></name><name><surname>Finn</surname> <given-names>R</given-names></name><name><surname>Blasberg</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography</article-title><source>Cancer Research</source><volume>58</volume><fpage>4333</fpage><lpage>4341</lpage><pub-id pub-id-type="pmid">9766661</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verboven</surname> <given-names>C</given-names></name><name><surname>Rabijns</surname> <given-names>A</given-names></name><name><surname>De Maeyer</surname> <given-names>M</given-names></name><name><surname>Van Baelen</surname> <given-names>H</given-names></name><name><surname>Bouillon</surname> <given-names>R</given-names></name><name><surname>De Ranter</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A structural basis for the unique binding features of the human vitamin D-binding protein</article-title><source>Nature Structural Biology</source><volume>9</volume><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1038/nsb754</pub-id><pub-id pub-id-type="pmid">11799400</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname> <given-names>J</given-names></name><name><surname>Rapsomaniki</surname> <given-names>MA</given-names></name><name><surname>Chevrier</surname> <given-names>S</given-names></name><name><surname>Anzeneder</surname> <given-names>T</given-names></name><name><surname>Langwieder</surname> <given-names>C</given-names></name><name><surname>Dykgers</surname> <given-names>A</given-names></name><name><surname>Rees</surname> <given-names>M</given-names></name><name><surname>Ramaswamy</surname> <given-names>A</given-names></name><name><surname>Muenst</surname> <given-names>S</given-names></name><name><surname>Soysal</surname> <given-names>SD</given-names></name><name><surname>Jacobs</surname> <given-names>A</given-names></name><name><surname>Windhager</surname> <given-names>J</given-names></name><name><surname>Silina</surname> <given-names>K</given-names></name><name><surname>van den Broek</surname> <given-names>M</given-names></name><name><surname>Dedes</surname> <given-names>KJ</given-names></name><name><surname>Rodríguez Martínez</surname> <given-names>M</given-names></name><name><surname>Weber</surname> <given-names>WP</given-names></name><name><surname>Bodenmiller</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Single-Cell atlas of the tumor and immune ecosystem of human breast Cancer</article-title><source>Cell</source><volume>177</volume><fpage>1330</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.03.005</pub-id><pub-id pub-id-type="pmid">30982598</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Kerketta</surname> <given-names>R</given-names></name><name><surname>Chuang</surname> <given-names>YL</given-names></name><name><surname>Dogra</surname> <given-names>P</given-names></name><name><surname>Butner</surname> <given-names>JD</given-names></name><name><surname>Brocato</surname> <given-names>TA</given-names></name><name><surname>Day</surname> <given-names>A</given-names></name><name><surname>Xu</surname> <given-names>R</given-names></name><name><surname>Shen</surname> <given-names>H</given-names></name><name><surname>Simbawa</surname> <given-names>E</given-names></name><name><surname>Al-Fhaid</surname> <given-names>AS</given-names></name><name><surname>Mahmoud</surname> <given-names>SR</given-names></name><name><surname>Curley</surname> <given-names>SA</given-names></name><name><surname>Ferrari</surname> <given-names>M</given-names></name><name><surname>Koay</surname> <given-names>EJ</given-names></name><name><surname>Cristini</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Theory and experimental validation of a Spatio-temporal model of chemotherapy transport to enhance tumor cell kill</article-title><source>PLOS Computational Biology</source><volume>12</volume><elocation-id>e1004969</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004969</pub-id><pub-id pub-id-type="pmid">27286441</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>Q</given-names></name><name><surname>Arnheim</surname> <given-names>AD</given-names></name><name><surname>Finley</surname> <given-names>SD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>In silico</italic> mouse study identifies tumour growth kinetics as biomarkers for the outcome of anti-angiogenic treatment</article-title><source>Journal of the Royal Society Interface</source><volume>15</volume><elocation-id>20180243</elocation-id><pub-id pub-id-type="doi">10.1098/rsif.2018.0243</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65145.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing Editor</role><aff><institution>James J Peters Veterans Affairs Medical Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This paper by Arap et al. utilizes phage display technology to identify a novel peptide that interacts with components of the Vitamin D receptor on tumor associated macrophages. To target this discovery to therapeutic advantage, a soluble peptide conjugated to cell suicide agents was created and found to suppress the growth of triple negative breast cancer cells in animal models.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The reviewers have opted to remain anonymous. The Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Summary:</p><p>Both reviewers noted the potential importance of the submission. However, both of them noted that some areas needed improvements, and specifically the role of vitamin D was highlighted. Given the extensive experimentation that both reviewers felt was largely sufficient for publication, a resubmission is encouraged focusing on addressing the relatively minor shortcomings noted below.</p><p>Essential Revisions:</p><p>Overall there are not a lot of significant revisions needed. The two listed below should be addressed for resubmission:</p><p>1. Both reviewers wanted additional information if the effects of peptide treatment are abrogated by excess vitamin D. Please ensure that evidence is included to address this topic.</p><p>2. Reviewer 1 aptly noted that the Discussion section is inadequate given the extensive data. Please expand the discussion to address questions brought up by both reviewers below. One additional topic for discussion not brought up by the reviewers, but that would be interesting is the potential to use this therapy in combination with other immunomodulatory drugs, which now have broad multi-tumor applications(i.e. those targeting the PD-L1 axis). Would is be possible to combine the two therapies to be synergistic?</p><p><italic>Reviewer #1:</italic></p><p>Overall Strengths: The paper has many strengths. Overall, it presents a novel function for a specific vitamin D receptor on type II tumor associated macrophages (Type II TAMS), a finding not previously made. It further provides experimental evidence that supports the possiblilty of this discovery having an eventual impact on the treatment of patients with Triple Negative Breast Cancer.</p><p>Importantly, the authors provide evidence that a specific nonapeptide CSSTRESAC activates the PDIA3 vitamin D receptor on TAMs, and further stimulates a pro-inflammatory cytokine response, likely further stimulating tumor aggressiveness.</p><p>Based on this novel discovery, the authors propose multiple approaches to interfering with the pro-tumorigenic Vitamin D-receptor TAM axis in Triple Negative Breast Cancer, an aggressive form of this disease. These include 1. Using a soluble form of the nonapeptide to blunt tumor growth, and 2. Using the peptide to target cell suicide moieties to the tumor. Both of these approaches proved effective at retarding tumor growth in the data presented in the manuscript and both represent novel approaches to the clinical management of Triple Negative Breast Cancer if they can be shown to be safe and effective. The targeting approach is of particular interest due to the continued success of the prostate-membrane-specific antigen (PSMA) in targeting both imaging radionuclides and antibody-drug conjugates to tumor sites. This type of tumor targeting is clearly gaining traction in clinical cancer therapy and new targeting modalities are sorely needed. The presentation of CSSTRESAC as a novel targeting agent for Triple Negative Breast Cancer and, one would expect, for other tumors with a strong M2 TAM response is potentially quite significant.</p><p>Technical Strengths:</p><p>This team leaders have worked on the use of phage display technology to identify biologically active peptides for many years and are certainly leaders in this field. The identification of CSSTRESAC as a vitamin D receptor ligand is a significant scientific advancement that would have been difficult to accomplish by other means.</p><p>The tumor experiments are well done and provide compelling evidence that use of the peptide can retard tumor growth in preclinical experiments.</p><p>The targeting experiments, both with phage and with conjugated peptide, provide confidence that this peptide, or future derivatives could be utilized to direct reagents to TAM infiltrated tumors, a potentially important clinical use.</p><p>Potential Weaknesses:</p><p>The possibility of toxicity during prolonged treatment with the CSSTRESAC peptide or its conjugates could be investigated more thoroughly,</p><p>Preliminary experiments suggest that binding of the receptor to the receptors is not stronger than the natural vitamin D components. Will this compromise the potential clinical utility of the approach?</p><p>Comments for authors:</p><p>The authors provide evidence that liver enzymes are not adversely affected by treatment with the peptide. They should also show weights of the animals treated with the peptide during the course of the tumor experiments.</p><p>The authors provide convincing evidence that PDIA3 expression on monocytes is a mediator of CSSTRESAC activity, and that peptide-expressing phage bind to PDIA3 and DBP. It would be worthwhile if they could show directly the affinity of the peptide binding to purified DBP and PDIA3, perhaps by nuclear plasmon resonance or another direct biochemical analysis.</p><p>In Figure 3, viral gene therapy appears to give a greater anti -TAM response but not a greater anti-tumor response. Is this a meaningful difference?</p><p>The authors provide computational molecular modeling to determine whether the nonapeptide is conformationally similar to vitamin D and determine that it should bind directly to DBP. As this reviewer is not sufficiently versed in that technology, others must weigh in on this data.</p><p>Inadequate Discussion:</p><p>While it is common to see manuscript discussions where the overlong conclusions are not justified by the amount or importance of the results, this paper represents the opposite case. Surely a manuscript with 8 plus pages of results, 14 pages of methods and approximately 60 data panels deserves more than one paragraph of discussion. There are many aspects of this paper where it would be worthwhile to hear the author's interpretation. Just a few of these are listed here, but I'm sure that other readers would want more.</p><p>a. Why a cyclic peptide vs a linear peptide?</p><p>b. What is the relevance to Vit D activity in macrophages in other contexts including inflammation and atherogenesis?</p><p>c. PDIA3 null mice were reported to show severe bone abnormalities. If true, would this impact the potential use of inhibiting this axis in patients with metastatic breast cancer where bone integrity might be compromised?</p><p>d. If the effects of peptide treatment are abrogated by excess vitamin D, would it be necessary to restrict vitamin D intake in patients undergoing treatment with soluble peptide?</p><p>e. Will determination of TAM infiltration be necessary to preselect patients who might be candidates for peptide therapy?</p><p><italic>Reviewer #2:</italic></p><p>This manuscript focuses on using phage display-based approach to identify peptides that target tumor associated macrophages to treat triple negative breast cancers (TNBC) and potentially other tumors that express the cell surface receptor PDIA3. The authors did an extensive and well-organized study that identified a peptide (CSSTRESAC) that appears as a mimetic to active vitamin D, and was found to bind to the vitamin D receptors DBP and PDIA3, the later of which is expressed on the surface of tumor macrophages (TAMs). They show that CSSRTESAC enhances a pro-inflammatory response that is tumor-inhibiting and thus could become a lead drug target.</p><p>The manuscript provides extensive supplementary data to well-support their investigations, and thus there are few short-comings. The one major area of weakness stems from the hypothesis that the CSSRTESAC peptide is serving as a vitamin D mimetic to exert its tumor-inhibiting effects. In Figure 2 the authors demonstrate that CSSRTESAC can induce a marked pro-inflammatory phenotype, however such effects are not seen by vitamin D, which the authors find could actually competitively inhibit the pro-inflammatory response. This interplay between CSSRTESAC and vitamin D was not explored in vivo unfortunately.</p><p>This is an interesting topic that identifies a potential immunomodulatory target that could be targeted. This has the potential to have a profound impact on oncology and thus overall with some revision should deserve publication.</p><p>Overall this is an outstanding and well-supported manuscript.</p><p>1. The one major area of weakness stems from the hypothesis that the CSSRTESAC peptide is serving as a vitamin D mimetic to exert its tumor-inhibiting effects. In Figure 2 the authors demonstrate that CSSRTESAC can induce a marked pro-inflammatory phenotype, however such effects are not seen by vitamin D, which the authors find could actually competitively inhibit the pro-inflammatory response. This interplay between CSSRTESAC and vitamin D was not explored in vivo. More mechanistic studies would have significantly strengthened the paper. Why does CSSRTESAC binding to PDIA3 induce a profound pro-inflammatory, tumor inhibiting response but stronger binding by vitamin D does not?</p><p>2. The main hypothesis is that CSSRTESAC induces changes in macrophages that lead to a pro-inflammatory response inhibiting tumor growth. What happens when the inflammatory response is inhibited? For example steroids are often used in many chemo regimens; what is the effect of CSSRTESAC on tumor growth when combined with steroids vs steroids alone? This again goes back to the question on mechanism.</p><p>3. There is a typo on line 210 of page 10: &quot;macrophage&quot; should read &quot;macrophages&quot;</p><p>4. Not sure if line 369 page 17 has a typo: &quot;incubated ON at&quot;. Perhaps this is correct, as I am not familiar with the methodology.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65145.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential Revisions:</p><p>Overall there are not a lot of significant revisions needed. The two listed below should be addressed for resubmission:</p><p>1. Both reviewers wanted additional information if the effects of peptide treatment are abrogated by excess vitamin D. Please ensure that evidence is included to address this topic.</p></disp-quote><p>Thank you for the opportunity to address this ligand-receptor interaction. We have now expanded our original Results and Discussion sections to emphasize the mathematical modeling projections used to assess the competitive nature of the binding interactions observed among the new cyclic ligand peptide CSSTRESAC, 1,25-(OH)<sub>2</sub>D<sub>3</sub>, and vitamin D-binding protein (VDB), along with their potential biochemical consequences for targeting in vivo. Our model accounts for two primary opposing processes: tumor cell growth and death caused by the CSSTRESAC peptide, while also allowing for competitive antagonism exhibited by 1,25-(OH)<sub>2</sub>D<sub>3</sub> in serum. If one assumes an adult mouse weight of ~20 g, and a volume of ~10 mL/kg for the peritoneal cavity, normal levels of total vitamin D in the peripheral blood are estimated at ~50 ng/mL, which is ~150 nM, of which only ~1% would be free to interact with CSSTRESAC. As such, at 10 mg/kg treatment dose, serum peak concentrations of soluble CSSTRESAC peptide are estimated at the μM range, and therefore unlikely to be competed off by the circulating 1,25-(OH)<sub>2</sub>D<sub>3</sub>. Moreover, we have now used a mathematical model to simulate a clinical trial of human breast cancer patients with soluble CSSTRESAC and the importance of a potential competitive binding between 1,25-(OH)<sub>2</sub>D<sub>3</sub> and CSSTRESAC in the serum (Figure 5 and Supplementary Figure 8). By comparing intravenous (IV) administration methods (i.e., infusion vs. bolus), our model predicted that an infusion setting would result in ~400 mm<sup>3</sup> greater reduction in tumor volume compared to bolus administration, without interference from the competing native 1,25-(OH)<sub>2</sub>D<sub>3</sub> in serum. These data have now been added to the revised Results (pp. 12-13) and revised Discussion (pp. 14-16).</p><disp-quote content-type="editor-comment"><p>2. Reviewer 1 aptly noted that the Discussion section is inadequate given the extensive data. Please expand the discussion to address questions brought up by both reviewers below.</p></disp-quote><p>We appreciate this insightful suggestion. We have now expanded the Discussion section of the original manuscript to incorporate the points raised by Reviewer 1 and have also discussed the potential use of CSSTRESAC-targeted therapies in combination with immunomodulatory drugs. These revisions can now be found in the revised manuscript (pp. 14-16).</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[…] Potential Weaknesses:</p><p>The possibility of toxicity during prolonged treatment with the CSSTRESAC peptide or its conjugates could be investigated more thoroughly,</p></disp-quote><p>Thank you. This has now been added to the revised Discussion (p. 14-16).</p><disp-quote content-type="editor-comment"><p>Preliminary experiments suggest that binding of the receptor to the receptors is not stronger than the natural vitamin D components. Will this compromise the potential clinical utility of the approach?</p></disp-quote><p>This is an important point. We have now introduced an in silico model to address the potential effects of serum 1,25-(OH)<sub>2</sub>D<sub>3</sub> on the therapeutic activity of soluble CSSTRESAC when administered into the circulation (revised Results and Discussion). Please see our more detailed response to point 1 of the Reviewing Editor.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>[…] 1. The one major area of weakness stems from the hypothesis that the CSSRTESAC peptide is serving as a vitamin D mimetic to exert its tumor-inhibiting effects. In Figure 2 the authors demonstrate that CSSRTESAC can induce a marked pro-inflammatory phenotype, however such effects are not seen by vitamin D, which the authors find could actually competitively inhibit the pro-inflammatory response. This interplay between CSSRTESAC and vitamin D was not explored in vivo. More mechanistic studies would have significantly strengthened the paper. Why does CSSRTESAC binding to PDIA3 induce a profound pro-inflammatory, tumor inhibiting response but stronger binding by vitamin D does not?</p></disp-quote><p>This is indeed an intriguing observation. Our current interpretation is that a pharmacological dose of soluble CSSTRESAC administered IV during treatment is likely to result in differential effects in PDIA3-expressing TAMs, which would not be observed when PDIA3 is exposed to physiological amounts of circulating 1,25-(OH)<sub>2</sub>D<sub>3</sub>. Alternatively, one might speculate that 1,25-(OH)<sub>2</sub>D<sub>3</sub> could perhaps lead to stimulation of both membrane- and nuclear-initiated steroid signaling while CSSTRESAC only stimulates membrane-initiated signaling pathways. Future studies will further clarify between these possible biochemical scenarios.</p><disp-quote content-type="editor-comment"><p>2. The main hypothesis is that CSSRTESAC induces changes in macrophages that lead to a pro-inflammatory response inhibiting tumor growth. What happens when the inflammatory response is inhibited? For example steroids are often used in many chemo regimens; what is the effect of CSSRTESAC on tumor growth when combined with steroids vs steroids alone? This again goes back to the question on mechanism.</p></disp-quote><p>This is a complex and ongoing line of mechanistic investigation that is now discussed in the revised manuscript. Future experiments will certainly shed light on the functional role(s) of the inflammatory response, but we think these are beyond the scope of the original discovery and early translational work reported here.</p></body></sub-article></article>